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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Karolinska Institute, Sweden 
 
VICE-CHAIR 
Professor Cornelia van Duijn 
Genetic epidemiology, Alzheimer’s disease and related disorders 
Erasmus Medical Centre, the Netherlands 
 
Professor Johanna Ivaska 
Molecular cell biology, cell adhesion, cancer biology 
University of Turku, VTT Technical Research Centre, Finland 
 
Professor Olli Lassila  
Immunology, medical microbiology 
University of Turku, Finland 
 
Professor Hans-Christian Pape 
Neuroscience, neurophysiology 
University of Münster, Germany 
 
Professor Thomas Ruzicka 
Dermatology, allergology 
Ludwig-Maximilians-Universität (LMU) München, Germany 
 
Professor Lars Terenius 
Experimental alcohol and drug dependence research, mental disorders, 
preventive medicine 
Karolinska Institute, Sweden 
 
Professor Peter York 
Physical pharmaceutics, pharmaceutical chemistry, pharmaceutical 
technology 
University of Bradford, Great Britain 
 
The panel, independently, evaluated all the submitted material and was responsible for the 
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Dr Seppo Saari, Doc., Senior Adviser in Evaluation, was responsible for the entire 
evaluation, its planning and implementation and acted as an Editor-in-chief of the 
reports. 
Dr Eeva Sievi, Doc., Adviser, was responsible for the registration and evaluation 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
  
4 
 
 
  
 
 
5 
 
1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
 
 
11 
 
Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The IndiViDrug RC is composed of 25 researchers at the Institute of Clinical Medicine and Department of 
Clinical Pharmacology, Faculty of Medicine, expertly led by six PIs, and is funded by the University of 
Helsinki (UH) and external grants. The focused research addresses the umbrella descriptions of individual 
variability in drug response and drug safety, covering the topics of drug interactions, pharmacogenetics 
and drug safety and pharmacokinetics in pregnant and young and old patient groups. The societal impact 
of these studies is immense with, for example, findings and outcomes from the research being 
incorporated internationally into clinical guidance documentation. 
The RC’s international cutting edge position in these areas has been strengthened during the 
evaluation period. Evidence is provided of breakthrough findings, and impressive statistics from all the 
bibliographic analyses for numbers of publications, citations and the high impact level of journals for work 
published across the disciplines of pharmacology, anaesthesiology, clinical neurology, neurosciences and 
toxicology. Additionally, the quality and scientific significance is reflected by Professor Neuvonen being 
recognised as an ISI Highly Cited Scientist (pharmacology) since 2005. 
Overall the RC is recognised as a pioneer in the subject of individualized drug therapy which maintains 
a status in the field as a hot topic. The RC is the leading national centre, and a world leading international 
multidisciplinary research team focused on the topics cited above. A clear and distinctive research profile 
with convincing future potential is expressed, with future plans well defined and addressable by this 
outstanding RC. 
Numeric evaluation: 5 (Outstanding) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
At the core of the doctoral training is the national Clinical Drug Research Graduate School (CDRGS), and 
the RC adheres to the related good practices and procedures from this source. Good practice is in place to 
cover student recruitment, selection, research programme management and thesis preparation and 
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defence, as well as en route by publishing findings in high ranking journals. The primary aim of doctoral 
programmes is to educate and train students in Good Clinical Practice (GCP) for carrying out drug 
research in various fields, and the RC is clearly successful in this ambition. Of the 11 PhDs awarded during 
the assessment period for doctorates exclusively from this RC, three received notable distinctions and 
awards – a commendable achievement and all doctorates are employed. With the current deficit in 
professional clinical drug researchers, the RC may consider what steps can be taken to increase the 
number of doctoral students whilst not diminishing the excellent levels of training and education provided. 
The RC staff makes major contributions to the CDRGS activities, including the organisation of graduate 
training courses (up to five per annum) which are open to researchers at the University of Helsinki and 
attract between 40 and 150 participants for each course. 
Funding for doctorate students is provided by the UH, CDRGS and the Academy of Finland, and it 
should be noted that some sources of funding (including some EU grants) are dependent on the 
pharmaceutical industry and thus may not be available to the RC which may be working in areas against 
the economic interests of this industry. Whilst this is clearly a potential funding issue, the RC together with 
other international colleagues in the field may wish to consider creating an international consortium to 
enter into creative and forward-looking discussion with relevant pharmaceutical company associations to 
address this issue. With growing interest and activity in individualized and personalized medicine by the 
pharma industry, the important knowledge from academic and clinic research sources in this field may 
now attract unbiased support. 
The RC has clear and sound plans for the future development of their doctoral training programmes, 
especially via the increased collaboration with other groups in Finland – including merging with 
FinPharmaNet in 2012 to provide uniform practices in doctoral training. The proposed increase in activity 
in paediatric clinical pharmacology via the European Global Research in Paediatrics is also appropriate and 
timely and is fully supported. 
Numeric evaluation: 5 (Outstanding) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The findings and outputs from the research of IndiViDrug have had, and continue to have, a major and 
direct impact on public health nationally and internationally via the contributions made to drug interaction 
databases, textbooks and treatment guidelines, especially for areas that include the treatment of pain, 
children and patients during pregnancy. 
The increased understanding of the mechanisms of drug interactions has also had major societal 
impact, and such research has enabled the recognition of potential drug interactions as well as, 
importantly, predicting such events. 
All the PIs and other members of the RC have made important contributions to expert panels and 
advisory groups for professional and clinical agencies. 
It is clear that the activities of IndiViDrug have provided major and substantial contributions to society, 
and will continue to do so. In addition, the RC communicated not only to the scientific community but also 
to the public one and thereby increasing the understanding of the problems and the benefit of this 
research focus. 
The plans to increase linkages to the pharma industry (see comment in 2.2 above) and the regulatory 
authorities are important and should be followed up with vigour, to ensure that the important research 
findings in individualized drug therapy find maximal benefit to society as a whole. 
Numeric evaluation: 5 (Outstanding) 
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2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The RC interacts closely with other research teams and groups in the field both domestically and 
internationally, and the PIs are all actively involved in the leading international networks of their areas of 
specialization within the RC’s research themes. More than 40 publications have resulted from joint 
collaborations with overseas research groups. Additionally, the PIs have been involved with joint 
supervision of PhD programmes overseas in some cases. 
The RC funds doctoral student mobility for research study periods overseas, and it is encouraging to 
note the good practice that all doctoral students present at one international congress annually. 
The plans to build on this sound foundation and efforts to increase internal collaborations with other 
RCs of UH are appropriate. Thereby, desired increase in collaboration with be facilitated, and all members 
of the new consortium will be able to share good practice and governance as well as the opportunity to 
improve, and possible share, infrastructure processes and systems. 
Numeric evaluation: 5 (Outstanding) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
The six PIs all have links into the Diagnostic and Therapeutic Department in the Institute of Clinical 
Medicine, and via individual PIs to the Departments of Clinical Pharmacology and Anaesthesiology. A well 
equipped clinical research unit is available, and crucially a research laboratory with high resolution 
analytical capabilities as well as being able to handle DNA samples and carry out genotyping. The 
maintenance and continuous improvement of analytical equipment in this laboratory is a key to the 
continuing excellence of the RC, and the proposed acquisition of the state of the art high specification 
LC/MS/MS spectrophotometer must be seen as a major priority. Access to other analytical tools not 
available in house is managed via the extensive collaborations of the RC, a feature that also helps to 
strengthen links with foreign leading research teams, and facilitate doctoral student visits. However, 
renewal of equipment and keeping instrumentation to ‘state-of-the art’ is always a challenging problem. 
Teaching and clinical duties of the RC staff, and especially the PIs are heavy, with four PIs having 30 – 
60% non-research duties, and two PIs up to 80 – 90% non-teaching responsibilities. Whilst such duties are 
recognised as very important, the RC is encouraged to search for ways to reduce these figures without 
disadvantaging the quality of clinical and teaching instruction. Increased allocation to research time would 
also facilitate the ambition to increase the number of doctoral students in the RC. 
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2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
The RC identifies the synergistic combination of the six PIs as a strength in the leadership and 
management of the research and doctoral training and uses the facilities and resource of the CDRGS 
graduate school to strengthen these processes. Given the high quality of the performances of the RC this 
system works well although the union into  FinPharmaNet may provide other options of good practice 
which may strengthen current processes. 
The retirement of PI Professor Neuvonen in 2011 poses a challenge to the group and the importance of 
replacement to ensure sustained high quality activity by the RC in related topics and maintaining external 
collaborations must be urgently addressed via appropriate channels in the UH. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The total funding during the assessment period is around €5m which, considering access to certain 
funding routes is not yet available to the RC, is a substantial sum and as a result of good success. It is 
noted that around 70% of external funding was from the Ministry of Education and Culture. Given the 
current economic issues on a global basis, the RC may wish to consider the likelihood of continued access 
to this level of resource from this governmental agency and search for alternative funding agencies (e.g. 
EU and industry – see comments in 2.2). 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
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The action plan is detailed and appropriate to maintaining the world leading cutting edge status of the 
InDiViDrug. Specific points within the plan have been highlighted above. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 1. The research of the participating community represents the international cutting edge in its field. 
 
From the entity of the evaluation material, it is clear that the InDiViDrug RC is at the forefront of 
international research in its field, and plans are in place to continue and strengthen this position. The 
participation category is thus Category 1, in that the research of the participating community represents 
the international cutting edge in its field. 
Numeric evaluation: 5 (Outstanding) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
The compilation process was balanced and fair, with PIs taking the leadership role in this process. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 6: Clinical research 
 
The key focus area of research and doctoral training of InDiViDrug fits perfectly into the UH’s focus are 6 – 
‘Clinical Research’. 
2.12 RC-specific main recommendations 
The Panel was impressed by the overall excellent quality of the documentation from, and bibliographic 
statistics related to, the RC. The Panel also supports the RC’s proposal to find ways to strengthen the 
number of doctoral supervisors and doctoral candidates, given the increasing need for such personnel. 
Other forward-looking plans were accepted and regarded as challenging yet realistic. 
Collaboration with other RCs in appropriate areas of mutual coalescence of interests, adding strength 
to both/all partners, is recommended. 
Efforts to increase the allocated time for the clinical staff for research are welcomed and appropriate. 
Further positive outcomes in this area are recommended. 
Given the high impact of the outputs and the societal impact from the RC, and the recognized 
importance of increasing dialogue with the pharmaceutical industry, it is suggested that consideration is 
given by the RC to take a lead in coordinating an international academic network which would aim to 
interface with pharma industry consortia and regulatory bodies. The goal would be to promote open 
exchange of the growing knowledge data base from the research activities of the RC (and other 
international research groups) to accelerate the introduction of new guidelines on individual variability in 
drug responses. Success in this space could lead to additional support and funding from pharma in an 
‘unbiased’ framework. 
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2.13 RC-specific conclusions 
The Panel wishes to congratulate the RC for their excellent work, and recognize the value of their various 
forms of output in providing deeper understanding in the important field of individual variability in 
response to drugs. The societal impact and potential benefits are enormous, and the attention directed 
towards the paediatric and elderly groups as well as pregnant mothers, is seen as critically important. 
A suggestion is made for the RC to lead an effort to increase dialogue and information exchange with 
the pharma industry and regulatory agencies to accelerate the introduction of new guidelines addressing 
patient variability to medicines. 
Efforts should continue to secure additional research time for clinical staff members of the RC, where 
appropriate. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
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         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Individual variability in drug response (IndiViDrug) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Janne Backman, Clinical Pharmacology, Institute of Clinical Medicine, Faculty of 
Medicine 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Backman, Janne 
E-mail:  
Phone: +358947173914 
Affiliation: Medical Faculty, Inst Clin Med, Department of Clinical Pharmacology 
Street address: Tukholmankatu 8C, 00290 Helsinki 
 
 
Name of the participating RC (max. 30 characters): Individual variability in drug response 
Acronym for the participating RC (max. 10 characters): IndiViDrug 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The “Individual variability in 
drug response - significance of drug interactions and pharmacogenetics” researcher community (RC) is 
characterized by a unique combination of competency in chemical analytics of drugs and their metabolites, 
expertise in pharmacokinetics, and deep understanding of drug interactions and pharmacogenetics, 
coupled with skills and capacity to carry out clinical research. The RC is formed by six internationally 
recognized principal investigators (Pertti J. Neuvonen, Mikko Niemi, Kalle Hoppu, Heli Malm, Eija Kalso and 
Janne T. Backman) and their research groups. The principal investigators have been working already before 
the evaluation period in close research collaboration on five focus areas related to the title of the RC: drug-
drug interactions (PJN, JTB, MN, EK), pharmacogenetics (MN, PJN, EK, JTB), and drug responses during 
pregnancy and lactation (HM, KH, PJN), in infants and children of different ages (KH, JTB, PJN, MN) and in 
treatment of pain (EK, JTB, PJN, KH). In these research topics, it has been essential to utilize the strengths of 
each individual research group, including pharmacokinetic (PJN, MN, JTB), pharmacogenetic (MN), 
teratologic (HM), pain medicine (EK) and pediatric (KH) expertise.  
The motivation for the collaboration has arisen from a common interest in drug safety, variability in drug 
response and individualization of drug treatment. All principal investigators have published original 
research papers with some or all of the other investigators, reflecting integrity of the RC. All principal 
investigators have also been actively collaborating and participating in doctoral training as senior 
researchers and supervisors (often joint supervision) in the national Clinical Drug Research Graduate School 
(CDRGS), which provides education and funding for doctoral students, and strengthens the operational 
basis of this RC. This RC actually forms an essential operational core unit of CDRGS, directed by PJN and JTB. 
All the principal investigators have collaborated as active organizers, lecturers and teachers on many of the 
postgraduate courses provided by CDRGS. 
 
 
 
1 RESPONSIBLE PERSON 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Pharmacology and Pharmacy 
RC's scientific subfield 2: --Select-- 
RC's scientific subfield 3: --Select-- 
RC's scientific subfield 4: --Select-- 
Other, if not in the list:  
 
 
Participation category: 1. Research of the participating community represents the international cutting 
edge in its field 
Justification for the selected participation category (MAX. 2200 characters with spaces):  During 2005-
2010, the RC has studied individual variability in drug metabolism and transport, and the efficacy and safety 
of drug treatments in special patient groups (e.g., pregnant women, children). The RC has uncovered many 
clinically important drug interactions, including those with lipid-lowering, cardiovascular, glucocorticoid, 
anti-infective, antidiabetic, antiasthmatic, analgesic and psychotropic drugs. The findings have markedly 
increased the understanding of the mechanisms of drug interactions related to the biotransformation and 
transport of drugs. In addition to directly improving patient care, and being commonly cited in clinical 
textbooks and guidelines, the findings of the RC’s systematic research have greatly improved the principles 
and guidelines applied in drug development, so that adverse drug interactions can now be predicted and 
studied at an early stage of drug development. Accordingly, the RC’s international cutting edge position in 
drug interaction research, achieved already years ago, was maintained or even strengthened during the 
evaluation period.  
In addition, during the last years, the RC has achieved a break-through in the pharmacogenetic focus area, 
reaching a cutting-edge position in transporter pharmacogenetics, as acknowledged by the Anders Jahre 
Prize for Young Scientists, awarded to MN in 2010. The pivotal studies were focused on the effects of 
transporter pharmacogenetics on the pharmacokinetics of statins. As a result, a gene test for SLCO1B1 
polymorphisms has already been implemented to clinical use. During recent years, pharmacogenetic 
research has been extended to novel target areas and drugs, and represents now a true cutting edge area 
raising considerable interest in the scientific society worldwide.  
In the wider context of variability in drug response, the RC is empowered by the international leading 
positions of its investigators. KH is the leading authority in the development of pediatric drug research and 
education networks both in Finland and in Europe, EK is in a leading position in international pain research 
community and HM is internationally networked in teratologic research. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): Drug 
therapy plays a central role in the treatment of most diseases. However, the response to drugs varies 
3 SCIENTIFIC FIELDS OF THE RC 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
widely between individuals, and only 25% to 80% of patients respond beneficially to a given drug therapy. 
On the other hand, some individuals cannot tolerate all drugs. In fact, adverse drug reactions have been 
found to cause about 7% of hospitalizations, and fatal adverse drug reactions have been estimated to be 
the fourth to sixth leading cause of death. Both anticipated positive health effects and unwanted toxicities 
of drugs are determined by a complex interplay of patient characteristics (e.g., age, body size, genes, sex, 
pregnancy and lactation, health, liver and kidney function) and environmental factors (e.g., diet, drug 
interactions). The research groups of the IndiViDrug RC carry out top quality clinical drug research in the 
following focus areas of interindividual variability in drug response: drug-drug interactions, 
pharmacogenetics, and drug responses during pregnancy and lactation, in infants and children of different 
ages and in the treatment of pain. In all the focus areas, the core of research is based on the profound 
understanding and know-how of the community in clinical drug research in special patient groups and in 
drug interactions and pharmacogenetic variability related to drug metabolism and transport. 
The research of the RC is strongly coupled with doctoral training via the national Clinical Drug Research 
Graduate School (CDRGS), and a majority of the RC’s original publications are included in doctoral theses. 
The main aim of the RC’s doctoral training is to educate Good Clinical Practice (GCP) level professional 
scientists for the planning, management and critical evaluation of clinical drug research in various fields of 
the society. The doctoral students take lessons on theoretical and professional skills, and perform relevant 
research to achieve a PhD degree within four years. Currently, there is a significant deficit of professional 
clinical drug researchers, which has, for example, caused significant delays in pharmaceutical drug 
development. Thus, there is a great societal demand for the doctoral training provided by the RC. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): As a RC focusing on clinical drug research and individual variability in drug 
response, the IndiViDrug RC strengthens the Medical Faculty’s profile as a high quality centre for clinical 
research and a pioneer in individualized drug therapy. Clinical drug research is also one of the functional 
focus areas of the RC’s home institute, Institute of Clinical Medicine. The main research areas, drug 
interactions and pharmacogenetic variability related to drug metabolism and transport, are currently the 
hottest areas of research in clinical pharmacology, which makes the RC and its home University extremely 
well known worldwide. The research of the RC is also generally highly influential, having a direct impact on 
the practice of drug therapy and also on the principles of clinical drug development. For example, the drug 
interaction and pharmacogenetic findings of the group have directly penetrated to treatment guidelines, 
drug interaction databases, and guidelines applied in pharmacokinetic research during drug development, 
which adds to the visibility of the University. Moreover, the RC attracts both national and international 
doctoral students and postdoctoral researchers more than it is possible to recruit, which increases the 
significance of the RC to the University.  
The RC plays an important role also in training clinical drug research professionals. The PI’s of the 
IndiViDrug community play a pivotal role in directing and organizing doctoral training within the national 
Clinical Drug Research Graduate School. The community has organized yearly about 5 postgraduate 
courses, with 40-150 participants in each, dealing with central topics of clinical drug research, e.g., methods 
in clinical drug research, pharmacogenetics, pharmacokinetics, pediatric drug research, 
pharmacoepidemiology, and adverse drug reactions. These courses are generally open to all doctoral 
students at the University of Helsinki. All the graduated doctors of the RC have been employed immediately 
after dissertation, which demonstrates the relevance and need of doctoral training provided by the RC. 
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Keywords: Drug interaction, pharmacogenetics, pharmacokinetics, drug metabolism, transport, pregnancy, 
lactation, children, pain medicine 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): In 2005-2010, the RC published 
groundbreaking findings concerning interindividual variability in drug response, with main focus on drug 
interactions, special patient groups and pharmacogenetics. During the period, the RC published about 160 
scientific articles in top international journals, i.e., about 27 articles/year. As many as 24 (15%) of them 
were published in the highest ranking journal publishing original research in clinical pharmacology (Clinical 
Pharmacology & Therapeutics, IF 6.96), and 8 (5%) of the articles in the highest ranking journal in 
anesthesiology (Pain, IF 5.37). Already by 30.11.2010, the total number of citations to the 160 articles was 
about 2200 (14/article), reflecting the high scientific quality of research. Many of them were cited 
frequently (26 articles cited at least 26 times). The relevance of the results is shown by their immediate 
penetration to treatment guidelines, drug interaction databases, and scientific principles applied in clinical 
drug development, enabling detection and prediction of adverse drug interactions at an early stage. One of 
the investigators (MN) was awarded The Anders Jahre Prize for Young Scientists in 2010 (a recognition of 
outstanding scientific achievements in the Nordic countries). One of the investigators (PJN) belongs to the 
Highly Cited Scientists within the category Pharmacology (www.isihighlycited.com) since 2005.  
The RC forms the core of the national Clinical Drug Research Graduate School, which provides education 
and funding for doctoral students, and is the mainstay of the high quality of doctoral training provided by 
the RC. The principal investigators have supervised 11 doctoral theses that were completed within the RC. 
Two of these were accepted with distinction (18% of theses), three were selected as the best clinical 
pharmacology theses in 2005, 2008 and 2009 in Finland, and one was awarded the best 2008 thesis by the 
University of Helsinki and by the Finnish Medical Journal. These awards, together with the high number of 
citations to the thesis work, reflect the high quality of the research and doctoral training. All the graduated 
doctors were employed immediately after dissertation. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): The RC’s scientific output should be assessed within the subject category 
Pharmacology & Pharmacy, based on the number of original articles per principal investigator, journal 
impact factors and the number of citations to articles. The number of citations can better reflect the quality 
and relevance of research than do impact factors. When comparisons between RCs in different subject 
categories are needed, bibliometric quality indicators (number of publications and citations, IF) should be 
related to the percent contribution of RC members to each publication and to journal ranking within its 
subject category, excluding review journals. Moreover, the quantitative output should be related to “full-
time principal investigator years” in 2005-2010, taking into account part-time affiliations and the load of 
teaching and administrative responsibilities of the investigators. In addition, the national and international 
prizes awarded to the investigators and their Highly Cited status should be acknowledged. External funding 
is not a fully appropriate quality criterion in the RC’s area focusing on adverse drug effects and interactions. 
Many grants, even EU grants, are dependent of pharmaceutical industry, and the RC’s research topics can 
be against their economic interest. 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
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Doctoral training can be evaluated by analyzing the number of completed and ongoing dissertations per 
number of RC’s professorship years. The quality of each doctoral training project is best evaluated by 
analyzing the sum of journal impact factors of each thesis and the ranks of these journals within the subject 
category, and by calculating the total number of citations to the original articles for each thesis. In addition, 
the evaluation should take into account the percentage of theses accepted with distinction and the awards 
given to them. Moreover, the quality could be evaluated by analyzing the doctoral training infrastructure 
and amount of postgraduate courses provided and organized by the RC. 
The publishing strategy of the RC is to produce high quality original research articles and publish a majority 
of them in the highest ranking journals in Pharmacology & Pharmacy and Anesthesiology. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Individual variability in drug response - significance of drug interactions and pharmacogenetics (IndiViDrug)
RC-LEADER J. Backman 
CATEGORY 1
Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 Ahonen Kati Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
2 Backman Janne x Clinical instructor, Docent Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
3 Fanta Samuel Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
4 Filppula Anne Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
5 Heiskanen Tarja Postdoctoral researcher
Medical Faculty, Institute of Clinical Medicine, Anaesthesiology and 
Helsinki University Central Hospital, Pain Clinic and Department of 
Anaesthesiology and Intensive Care Medicine
6 Hoppu Kalle x Senior researcher, Docent 
Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacology 
& HUSLAB
7 Honkalammi Johanna Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
8 Isohanni Mika Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
9 Jaakkola Tiina Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
10 Kajosaari Lauri Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
11 Kalliokoski Annikka Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy
12 Kalso Eija x Professor Medical Faculty, Institute of Clinical Medicine, Anaesthesiology
13 Pitkänen (Karjalainen)Marjo Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
14 Karonen Tiina Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
15 Keskitalo Jenni Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
16 Lilja Jari
Postdoctoral researcher, 
Docent
Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
17 Malm Heli x
Doctoral candidate - 
postdoctoral researcher
Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacology 
& HUSLAB
18 Neuvonen Pertti x Professor Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
19 Niemi Mikko x
University researcher - 
Professor 
Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
20 Pasanen Marja Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
21 Ruokoniemi Päivi Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
22 Schröder (Granfors)Marika Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
23 Tapaninen Tuija Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
24 Tornio Aleksi Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
25 Xiang Xiaoqiang Doctoral candidate Medical Faculty, Institute of Clinical Medicine, Clinical Pharmacololy 
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Name of the RC’s responsible person: Backman, Janne Tapio 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Individual variability in drug response, IndiViDrug 
The RC’s research represents the following key focus area of UH: 6. Kliininen tutkimus – Clinical research 
Comments for selecting/not selecting the key focus area: The key focus area of the RC's research and 
doctoral training is clinical drug research (variability in drug response - significance of drug interactions and 
pharmacogenetics). 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The focus has been in the factors causing individual variability in drug response, particularly in the effect 
of drug interactions and pharmacogenetics (Appendix 1, Figure 1). Also the effect of immature and 
developing body functions, fragility, and pregnancy on drug safety has been studied. The importance of 
the research focus is underlined by the reports that drugs cause about 100 000 deaths annually in the 
USA. During 2005-10, The RC has published about 175 publications in international journals, many of 
which are leading journals of their field. These publications have been cited about 2800 times (by 
28.2.2011). The quality and scientific significance is reflected also by the fact that one of the RC 
members (PJN) has been an ISIHighlyCitedScientist (pharmacology) since 2005 – there are not too many 
Finnish scientists ranked in this list. 
 
1. Drug interactions  
 
Most drugs are eliminated by drug metabolism, a process where microsomal cytochrome-P450 (CYP) 
enzymes are crucial. However, the role of specific CYP isoenzymes in the metabolism of several drugs is 
unknown.  
 
Research question: Our hypothesis was that there is inadequate or misleading product information 
regarding the metabolism of many drugs and their liability to interactions, and that even unrecognized 
interaction mechanisms may exist between drugs in clinical use. 
 
Results.  
 
The RC has uncovered several previously unknown adverse drug interactions, including those with 
opioids, lipid-lowering drugs, cardiovascular drugs, glucocorticoids, anti-infectives, oral antidiabetics, 
antiasthmatics, and psychotropic drugs and NSAIDs. These findings were not based on “fishing” 
experimentation but on deep evaluation and understanding of the properties of potential victim and 
“perpetrator” drugs. Our experience in the field and innovative in vitro studies guided us to perform 
targeted drug interaction studies in humans. Drug interactions causing 5-10-fold or even more increased 
exposures to the victim drug (e.g. between rofecoxib-tizanidine, gemfibrozil-repaglinide) or drastic 
BACKGROUND INFORMATION 
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decreases in drug concentration (e.g. rifampicin-oxycodone) were found. Our results have significantly 
improved the safety of drug treatment, and are cited in textbooks, guidelines and interaction alerts 
world-widely. 
 
The RC has identified the previously unrecognized important role of the CYP2C8 isoenzyme as a 
mediator of many drug interactions. The RC showed that CYP2C8 is the crucial isoenzyme in the 
metabolism of repaglinide, pioglitazone, rosiglitazone, cerivastatin, and montelukast. Other enzymes 
had been reported to be crucial by drug companies, because they had used irrelevant substrate 
concentrations in their studies.  
 
The RC has found and validated several new tools and probe drugs to be used in interaction research in 
humans. Many of these findings have been implemented to the guidelines of, e.g., FDA and EMEA. Our 
results and recommendations have significantly improved the interaction research principles applied in 
Pharma industry, so that interactions can now be better predicted already during drug development. 
Drug interaction research has become one of the main topics within clinical pharmacology, and the RC’s 
has the international cutting edge position in drug interaction research.  
 
2. Pharmacogenetics 
  
The understanding of the role of various membrane transporters in the pharmacokinetics and effects of 
different drugs has been in its infancy until recent years. Also the significance of pharmacogenetics in 
the variation of drug response and interactions has been poorly understood. 
 
Our Research target was a clarification of potential importance of certain cell membrane transporters, 
particularly of organic anion transporting polypeptides (OATPs), P-glycoprotein, and breast cancer 
resistance protein (BCRP) in the pharmacokinetics of statins and some other drugs, and to resolve the 
significance of pharmacogenetic polymorphisms in these transporter functions and in interindividual 
variation in drug exposure and risk of muscle toxicity of statins.  
 
Results 
 
The RC has shown that OATP1B1 has a crucial role in the liver uptake of many statins, and that its effect 
on different statins and their metabolites varies greatly between humans. A genetic polymorphism 
causing impaired OATP1B1 function increased the average plasma exposure to the active simvastatin 
acid more than 3-fold, to atorvastatin more than 2-fold, and to pravastatin and rosuvastatin nearly 2-
fold, but had no effect on fluvastatin. These findings were the first to demonstrate the diverse effect of 
a SNP on the pharmacokinetics of different statins and allowed us to predict the effect of SLCO1B1 
(encoding OATP1B1) polymorphism on the risk of dose-dependent muscle toxicity of simvastatin and 
other statins. Recent large scale pharmacoepidemiologic studies (e.g. SEARCH) have confirmed the 
relevance of our findings. The RC also demonstrated that the geographic distribution of the SLCO1B1 
polymorphism varies greatly. Genetic differences between populations correlated well with the 
geographical distances considering likely routes of migration of humans out of Africa. The functionally 
significant *1B haplotype showed the highest frequencies in populations near the equator, whereas the 
frequency of *15 increased toward north. The data suggest that natural selection may have shaped the 
global distribution of SLCO1B1 variants. 
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The RC has shown that a polymorphism in the ABCG2 gene, which causes a reduced activity of the BCRP 
transporter, considerably increases the exposure to atorvastatin, rosuvastatin, fluvastatin and 
simvastatin lactone but has no profound effect on the pharmacokinetics of pravastatin or simvastatin 
acid. The RC has also shown that a common haplotype of the ABCB1 gene (encoding the efflux 
transporter P-glycoprotein) increases the exposure to simvastatin acid and atorvastatin, without 
significant effects on the pharmacokinetics of fluvastatin, pravastatin, lovastatin and rosuvastatin. 
 
The RC has achieved a break-through in the pharmacogenetic focus area, reaching a cutting-edge 
position in transporter pharmacogenetics, as acknowledged by the Anders Jahre Prize for Young 
Scientists, awarded to MN in 2010, and by the Helsinki University´s best doctoral thesis award (to Marja 
Pasanen in 2009). The pharmacogenetic research has been extended to novel target areas and drugs, 
and represents now a true cutting edge area raising considerable interest in the scientific society 
worldwide. 
 
3. Pregnancy, immature body functions and fragility. 
 
Research question: The effects of pregnancy and lactation, immature and developing body functions, 
and fragility on drug response, pharmacokinetics and drug safety are not known although many drugs 
are used in patients belonging to these groups.  
 
Results. The safety of drugs, particularly of serotonin reuptake inhibitors, during pregnancy and lactation 
was evaluated in pharmacoepidemiologic studies, which have expanded to an ongoing EU- and NIH-
supported research network. The pharmacokinetics or effects of cyclosporine, fluconazole, pravastatin, 
and triptans in children and adolescent differed from those in adults underlining the need of dosing 
guidelines based on the maturation status of these patients. Considerably increased exposures to 
intravenous and oral oxycodone and paracetamol occurred in elderly patients, when the doses were not 
decreased from those used in younger adults. 
 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
The RC will continue in the present topic areas - the factors causing variability in drug response - also 
during the next 3-5 years. The quality of research will be further developed by 
 
1) Closer co-operation with clinicians and researchers at FIMM and Pharmaceutical Faculty. The effect of 
pharmacogenetics, drug-drug interactions, nutrient-drug interactions and membrane transporters on 
variability in drug response, and as a cause of adverse drug effects, will be studied in more detail. 
 
2) Information technology will be applied to identify factors explaining unusual drug response. In vitro – 
in vivo simulations of drug-drug interactions will be developed. Pharmacokinetic-pharmacodynamic 
modelling and population pharmacokinetics will be applied to experimental and clinical data.   
     
3) Post-doctoral researchers will be recruited to the RC to improve the supervision of doctoral students 
and to strengthen the quality of research. 
 
4) Updating the LC-MS/MS equipment in the laboratory of clinical pharmacology to allow highly 
sensitive analytics of drugs and their metabolites. 
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Main scientific field of the RC’s research:  
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
The doctoral training of the IndiViDrug researcher community (RC) is based on the efforts of six 
internationally recognized principal investigators (Pertti J. Neuvonen, Mikko Niemi, Kalle Hoppu, Heli 
Malm, Eija Kalso and Janne T. Backman; Appendix 1, Figure 2). Their closely collaborating research 
groups are focused on areas related to individual variability in drug response.  
 
The principal investigators of the RC have supervised 11 doctoral theses that have been completed 
during the evaluation period in the RC (and a number of theses not in the scope of the RC). Two of them 
were accepted with distinction (Annikka Kalliokoski and Marja Pasanen), and three of them were 
awarded the annual best thesis award of the Finnish Society for Clinical Pharmacology and Therapeutics 
(Marika Granfors, Marja Pasanen and Samuel Fanta). Marja Pasanen also got the Finnish 
Pharmacological Society (2009), University of Helsinki (2010), and Finnish Medical Journal (2010) thesis 
awards. These awards and distinctions are clear indicators of the exceptionally high quality of the RC’s 
doctoral training and its practices. In addition to the above mentioned theses, the investigators have 
participated as co-supervisors in a similar number of other thesis projects and are currently supervising 
about 10 ongoing thesis projects. 
 
The research of the RC is strongly coupled with doctoral training via the national Clinical Drug Research 
Graduate School (CDRGS, funded by the Ministry of Education and Culture), which is directed by two of 
the principal investigators of the RC (PJN and JTB). All principal investigators of the RC have been 
actively collaborating and participating in the CDRGS. CDRGS provides doctoral training in the following 
universities: University of Helsinki, University of Turku, University of Tampere, University of Eastern 
Finland (Kuopio) and University of Oulu. During 2005-2010 altogether 32 PhD theses have been 
completed in CDRGS. CDRGS has had 5-9 annual national graduate school positions during the 
evaluation period. This graduate school provides education and funding for doctoral students, and forms 
the operational core of the RC’s doctoral training. All the principal investigators have collaborated as 
active organizers, lecturers and teachers on many of the postgraduate courses provided by CDRGS. In 
addition to the graduate school positions, the RC has 3 training positions that have been available for 
doctoral students. 
 
The main aim of the RC’s doctoral training is to educate Good Clinical Practice (GCP) level professional 
scientists for the planning, management and critical evaluation of clinical drug research in various fields 
of the society. The doctoral students take lessons on theoretical and professional skills, and perform 
relevant research to achieve a PhD degree within four years. All doctoral students working in the 
IndiViDrug research groups have the possibility to join CDRGS. Accordingly, the principles and practices 
of doctoral training in the RC are based on the practices applied by the CDRGS, as well as on the 
principles of the Medical Faculty. In the RC, graduate school and other training positions are announced 
in national newspapers, in web based media (University website, CDRGS website), and via research 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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networks, when new positions become available (approximately once in 1-2 years). Selected positions 
can also be announced internationally. Both domestic and foreign applications are accepted. 
 
The evaluation of the applicants is carried out by the principal investigators of the RC, and in case of 
graduate school positions, by the Board of the CDRGS graduate school. Doctoral candidates are selected 
on the basis of the quality and suitability of the research protocol and the applicant’s personal 
competence (education and skills, previous experience). In clinical drug research in patients and healthy 
volunteers, a prerequisite for the candidates is usually MD education and a good command of Finnish 
(and/or Swedish) language. This limits the possibilities of the RC in recruiting foreign students. Despite 
this limitation, highly qualified foreign students have been selected regularly for laboratory oriented 
research projects in the RC.  
 
The recommendation of the RC is that, in order to ensure adequate supervision and high quality of 
doctoral training, each doctoral candidate has two qualified and dedicated principal supervisors and 
additional co-supervisors as necessary. The principle of the RC is that the supervisors take the 
responsibility of the feasibility, progress, and scientific quality of the thesis project. Thus, in addition to 
the motivation, skills and efforts of the candidate, supervisors are a critical component in the quality 
assurance of doctoral training. If necessary, doctoral training is carried out in collaboration with other 
departments and faculties. A good example of international collaboration is the thesis of Samuel Fanta, 
in which all original publications were carried out in collaboration with a Swedish research group (Mats 
Karlsson in University of Uppsala, who also provided co-supervision to the project).  
 
In the beginning of the project, each candidate makes a detailed doctoral training plan, including a 
research protocol and an outline of suitable theoretical courses. The RC also recommends a thesis 
committee of 2-3 external experts. The progress and quality of each thesis project, including research 
and theoretical studies, is controlled annually by the supervisors and in regular thesis committee 
meetings. If there are concerns about the progress of the thesis project (eg exceeding 3-4 years of full-
time work), the supervisors and thesis committee will consider changes to the initial protocol. 
 
In the RC, postgraduate courses are organized in close collaboration with CDRGS and with other national 
FinPharmaNet graduate schools: Drug Discovery Graduate School (DDGS), Graduate School in 
Pharmaceutical research (GSPR) and Finnish Graduate School in Toxicology (ToxGS). These graduate 
schools are active both in the Medical Faculty and in The Faculty of Pharmacy. This collaboration 
enables, on a national level, the availability of multidisciplinary courses covering all aspects of 
pharmacology and drug research, and is a strong asset of the RC. Together with the CDRGS, the RC has 
been responsible for the organization of 6-10 postgraduate courses annually, covering topics of clinical 
drug research, such as methods in clinical drug research, pharmacokinetics, pharmacogenetics, 
pharmacoepidemiology, pediatric drug research, adverse effects of drugs and career perspectives in the 
area of clinical drug research. In many of the courses, the language is English, and the lecturers are 
internationally recognized or even foreign experts. 
 
All graduated doctorates have been employed immediately after graduation, both to the public and 
private sectors. The training provided by the RC produces researchers that are skilled in the design, 
conduct and critical evaluation of clinical drug investigations. Such researchers and experts are highly 
demanded in the industry as well as in the public sector, and at present there is actually a shortage of 
trained professionals in clinical drug research in Finland, which has, for example, caused significant 
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delays in pharmaceutical drug development. Thus, there is a great societal demand for the doctoral 
training provided by the RC. Therefore, the content and focus of the training provided by the RC 
ascertains excellent career perspectives for the doctorates. 
 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
The strengths are 1) the attractive, clinically relevant research topics, 2) the resources of CDRGS (5-9 
graduate school positions; Academy of Finland funding for courses and travel expenses; good practices), 
and 3) the balanced training program, covering design, conduct and evaluation of clinical drug 
investigations. The challenges are 1) how to develop supervisor and training resources in various aspects 
of clinical drug research, 2) how to improve practices, and 3) how to motivate researchers to post-doc 
visits abroad. 
 
The doctoral training will be developed, e.g., as follows: 1) The RC will strengthen collaboration with the 
FinPharmaNet graduate schools, DDGS, GSPR and ToxGS, which will unite with CDRGS in 2012 to the 
FinPharma Doctoral Program, FPDP, where CDRGS acts as a separate sector (led by J Backman). 
Thereafter, the RC will adapt uniform practices with FPDP, including e.g., obligatory thesis committees. 
2) The RC will develop its resources in pediatric clinical pharmacology via the European ”Global Research 
in Paediatrics (GRIP)” training program chaired by K Hoppu. 
 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The RC has uncovered many clinically important drug interactions, and made findings concerning drug 
treatment of pain, and drug treatments in children and during pregnancy. Many findings have been 
implemented to drug interaction databases (e.g., SFINX), textbooks and treatment guidelines, available 
for physicians around the world. Thus, by directly improving patient care, the findings have a positive 
public health impact. Moreover, the RC’s systematic research findings have markedly increased the 
understanding of the mechanisms of drug interactions involving metabolism and transport of drugs, and 
improved the principles applied in drug development, so that adverse drug interactions can be predicted 
and studied early. Moreover, drug information producing companies (e.g., Medbase) directly benefit 
from the research of the RC. These developments have a remarkable societal impact to public and 
private sectors. 
 
The pharmacogenetic studies of the RC uncovered new effects of transporter pharmacogenetics on 
statin pharmacokinetics. A test for SLCO1B1 genetic variants, predicting muscle toxicity of statins, has 
already been implemented to clinical use in several countries, highlighting the impact of the work on 
principles of medical treatment. The methodology used by the RC serves as an example on how to 
design pharmacogenetic studies so that basic research findings can be translated to the clinic with a 
seamless chain of evidence in a cost-effective manner and with great confidence to findings.  
The RC has research collaboration with the industry, and some joint publications are under preparation. 
For obvious reasons, i.e., the principal research focus of the RC is on issues related to drug safety, the 
findings are more of the interest to the public sector than to industry, and there are few possibilities for 
collaboration with Pharma industry. 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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The leading expert positions of the investigators are part of the RC’s societal impact (Appendix 1, Figure 
2). Backman, Neuvonen and Niemi are important national-level experts in clinical pharmacology and 
pharmacogenetics. They have crucially contributed to national doctoral training in the CDRGS graduate 
school (PN is the founder and leader). E Kalso has a leading position in pain medicine (President of 
International Association for the Study of Pain), K Hoppu in pediatric pharmacology (board member of 
International Union of Pharmacology and Clinical Pharmacology, chairman of Pediatric Pharmacology 
Section), and Heli Malm in teratology (internationally networked). K Hoppu is also a leading authority in 
the development of pediatric pharmacology networks in Europe. 
 
In doctoral training, the RC has collaborated with national authorities and industry. Many employees of 
the authorities and industry have joined the RC and doctorates from the RC have been employed by the 
authorities and industry. Both sectors have a representative in the Board of the graduate school 
network (FinPharmaNet) of CDRGS. Doctorates have also been employed in public sector organizations 
and the public health system. The researchers and experts educated by the RC are highly demanded, 
and there is even a shortage of trained professionals in clinical drug research in Finland. Thus, there is a 
great societal demand for the training provided by the RC. 
 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
The societal impact of the RC's research and doctoral training can be strengthened by improving the 
integration of the industry and authorities to the work of the RC. To this end, joint research and 
education projects are already being prepared, and the roles of these sectors will be strengthened in the 
future FinPharma Doctoral Program. For example, these sectors will be utilized in the planning of the 
doctoral program curriculum and in the planning and conduct of collaborative doctoral training courses. 
 
For the Finnish society, it will be extremely important to respond to the high demand of professionals in 
clinical drug research. Therefore, the RC is seeking ways to increase the number of supervisor and 
graduate student positions in the university, in order to guarantee an adequate output of doctorates in 
clinical drug research in the future. 
 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The principal investigators of the RC are strongly networked with domestic and foreign research groups. 
The principal investigators are active participants of, e.g., the European Association for Clinical 
Pharmacology and Therapeutics, European Research Network on Pharmacogenetics/genomics, 
International Transporter Consortium, International Association for the Study of Pain, European 
Network of Teratology Information Services, and the Global Research in Paediatrics (GRIP) Network. The 
principal investigators were commonly invited to give talks in international congresses during 2005-
2010. These and other international research collaborations have resulted in more than 40 joint 
publications with foreign research groups during 2005-2010 (more than 30 original articles and 10 
reviews, letters and editorials). 
 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
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In addition to the doctoral theses carried out within the RC, the principal investigators have been 
actively participating in thesis supervision outside the RC. For example, Professor Pertti Neuvonen has 
co-supervised six doctoral theses for the University of Turku and one for the University of Helsinki during 
2005-2010. The doctoral thesis work of Dr. Samuel Fanta, supervised by Drs. Janne Backman and Kalle 
Hoppu, was carried out in collaboration with the University of Uppsala, Sweden. Moreover, a number of 
doctoral thesis articles have been published in collaboration with international research groups (e.g., 
Jenni Keskitalo’s work in collaboration with the University of Erlangen-Nuremberg, Germany). The RC 
has supported doctoral student mobility by providing funding for research stays abroad through the 
CDRGS or research grants. All doctoral students have presented their results in at least one international 
congress per year. 
 
Collaborators: 
 
1. Drug interactions 
University of Uppsala, Sweden 
- e.g., Prof. Marja-Liisa Dahl 
Karolinska Institute, Stockholm, Sweden 
- e.g., Prof. Anders Rane, Prof. Leif Bertilsson 
Université Paris Sud, Paris, France 
- e.g., Prof. Laurent Becquemont 
University of Bonn, Germany 
- e.g., Prof. Klaus von Bergmann 
University of Turku, Finland 
- e.g., Prof. Klaus Olkkola, Dr. Kari Laine 
 
2. Pharmacogenetics 
Karolinska Institute, Stockholm, Sweden 
- e.g., Prof. Magnus Ingelman-Sundberg, Prof. Leif Bertilsson 
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany 
- e.g., Prof. Matthias Schwab, Prof. Ulrich Zanger, Prof. Michel Eichelbaum 
University of Erlangen-Nuremberg, Germany 
- e.g., Prof. Martin Fromm 
University of Newcastle, UK 
- e.g., Prof. Ann Daly 
Baylor College of Medicine, Houston, Texas, United States 
- e.g., Prof. Suzanne Leal 
 
3. Pregnancy, immature body functions and fragility 
GRIP network (19 collaborating centers) 
University of Uppsala, Sweden 
- e.g., Prof. Mats Karlsson 
Queen’s University of Belfast, UK- e.g., Dr. Daniel McAuley 
Sackler Institute, Columbia University, New York, USA 
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 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
The high international reputation of the RC and the high degree of networking by the principal 
investigators provides an excellent ground for researcher collaboration and mobility in the future. The 
following actions are planned for developments: 
 
1. Strengthening international collaboration: 
Internationally established research leaders will be invited to Finland for research stays or to give talks 
in symposia. The RC will continue to organize symposia on its focus areas, with regular invitations to 
foreign speakers. The RC members will actively participate in international networks and continue to 
present their results in international congresses. 
 
2. Strengthening national collaboration: 
Collaboration between Finnish research groups will be facilitated by union of the FinPharmaNet 
graduate schools to the FinPharma Doctoral Program in 2012. To enable exchange of ideas and research 
collaboration in pharmacogenetics, a national research network will be established. The first step was 
taken in 2010, when RC members organized a pharmacogenetics workshop of 40 key researchers. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
The six principal investigators of the RC are connected to the Diagnostic-Therapeutic Department of the 
Institute of Clinical Medicine. Within the Department, J Backman (Clinical lecturer), P Neuvonen 
(Professor of Clinical Pharmacology and Director of the Diagnostic-Therapeutic Department) and M 
Niemi (Professor of Pharmacogenetics) are affiliated to the Department of Clinical Pharmacology. Also H 
Malm (senior physician) in the Teratology Information Service and K Hoppu (chief physician) in the 
Poison Information Service are connected to this university department. The position of E Kalso 
(Professor of Pain Research and Management, and Director of the Multidisciplinary Pain Clinic) is 
located in the Department of Anesthesiology (a suborganization of the Diagnostic-Therapeutic 
Department). 
 
The research facilities of the Department of Clinical Pharmacology include a well-equipped clinical 
research unit, which is especially suitable for pharmacokinetic studies and can accommodate up to 15 
research patients, and a modern research laboratory in Biomedicum Helsinki 1. The laboratory includes 
specialized personnel and equipment for analysis of drug and metabolite concentrations in biological 
samples, and for in vitro assays of drug metabolism and transport, and genotyping. The most 
sophisticated piece of analytical equipment is the API 3000 LC/MS/MS system, which is suitable for 
quantification of concentrations in the low nanomolar range and has been in extensive and continuous 
(24/7) use for the last 12 years. In addition, the ”work-horses” of the laboratory include two API 2000 
LC/MS/MS systems and several liquid chromatography systems. Moreover, the laboratory has 
infrastructure for preparation of DNA samples, and for genotyping (e.g., Applied Biosystems 7300 Real-
Time PCR system). The facilities have been at the disposal of the whole RC, and have been crucial to the 
research carried out. 
The RC can also directly utilize the clinical research facilities of the Pain Clinic (directed by E Kalso) and 
the facilities of the Poison Information and Teratology Information Centers. Moreover, the principal 
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investigators have excellent connections to clinical collaborators in the Meilahti Campus (e.g., Children’s 
Hospital and Meilahti Hospital) and to foreign research groups (e.g., Swedish, German and British 
groups) that have produced many joint publications. 
 
The investigators have been heavily occupied by duties not related to research. Neuvonen and Backman 
have been responsible for a 7.5 international credit course of clinical pharmacology to 120-130 medical 
students, specialist training in clinical pharmacology, a clinical pharmacology consultation service to 
physicians, and expert roles in the therapeutic drug monitoring services of the Hospital laboratory. 
These duties have required about 30-40% of their working hours. Similarly, E Kalso has been occupied by 
teaching pain medicine and M Niemi has been responsible (on a national level) for teaching 
pharmacogenetics since 2009. Considering their clinical responsibilities, their burden of non-research 
duties varies from 30-60%. H Malm and K Hoppu have full time clinical affiliations with 80-90% non-
research burdens. 
 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
The strengths of the operational conditions are the excellent laboratory facilities and the well-equipped 
facilities and experience of the investigators for clinical drug research. The main challenges are that the 
chemical analytical equipment is becoming outdated and old, and that the principal investigators can 
invest only part of their time for research and doctoral training.  
 
The RC is planning to acquire funding for a highly sensitive up-to-date LC/MS/MS system (requires about 
400.000 €) that would enable quantification of the very low plasma concentrations of modern drugs and 
quantification from very small sample volumes (which is a prerequisite for studies in children and in 
critically ill patients). Moreover, with acquired funding for the GRIP project (pediatric clinical 
pharmacology training involving doctoral training) and for a teratology research network, both Kalle 
Hoppu and Heli Malm will be able to increase their possibilities for research duties by 30-60% in the next 
four years. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
All principal investigators of the RC work as independent researchers and leaders of their own research 
groups, with formal management-related roles in their own units. There is no formal organization in the 
RC. However, all the principal investigators are involved in the CDRGS graduate school and actually form 
the core operational unit of the CDRGS in Helsinki, and all the research of the RC is heavily dependent 
on collaboration between investigators and on the core laboratory facilities of the Department of 
Clinical Pharmacology. Accordingly, the practical operational leadership and management of the RC are 
localized at the Department of Clinical Pharmacology, the home unit of CDRGS (led currently by Pertti 
Neuvonen, and after his retirement by Janne Backman). In addition, the leadership- and management-
related processes of the RC are based on the good practices of CDRGS, as described in section 2, leaving 
a lot of independence to the investigators. 
6 LEADERSHIP AND MANAGEMENT IN THE RESEARCHER COMMUNITY (MAX. 4400 CHARACTERS WITH SPACES) 
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This kind of organization guarantees high quality of research, because this way, the facilities and the 
expertise/know-how of the Department of Clinical Pharmacology can be utilized by all the principal 
investigators. The excellence of the core facilities of the department also strongly supports the research 
focus of the RC. Collaboration between experts of different areas (clinical pharmacology, 
pharmacokinetics, pharmacogenetics, pain medicine, pediatrics, teratology) is also important for the 
quality of research. The CDRGS graduate school strengthens collaboration between the investigators 
and other researchers, because of the requirements of the graduate school for the supervision of 
doctoral students, and because all researchers are involved in the training provided by CDRGS. During 
the evaluation period 2005-2010, most of the doctoral students in the RC were supervised and co-
supervised by at least 2-3 of the principal investigators, highlighting the strength of collaboration 
between the principal investigators. 
 
 
 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
A major strength of the RC’s leadership and management is the unique and synergistic combination of 
six independent principal investigators, who are all internationally known top researchers in their 
respective fields. The different backgrounds of the principal investigators bring synergy to the RC’s 
research efforts aiming at a shared and coherent target: understanding variability in drug response in 
order to improve the safety and efficacy of drug therapy. 
 
The main future challenges are related to the uncertainties of the interregnum time due to the 
retirement of Professor Pertti Neuvonen in 2011. Continuity of research during the interregnum period 
will be facilitated by transfer of the CDRGS leadership from Professor Neuvonen to Janne Backman. 
 
In addition, potential challenges arise from the budgetary limitations at the University of Helsinki. 
Therefore, the RC aims to secure sufficient funding for doctoral student and senior researcher positions, 
as well as for research infrastructure and other expenses. 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 437420 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 220000 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 0 
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 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 0 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Sigrid Juselius Foundation 
- Gyllenberg Foundation 
- Syöpäjärjestöt 
- Finska Läkaresällskapet 
- total amount of funding (in euros) from the above-mentioned foundations: 698350 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations:  
- total amount of funding (in euros) from the above-mentioned funding organizations: 0 
 
 Other national funding (incl. EVO funding) - names of other national funding organizations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros). 
- names of the funding organizations: EVO 
- Ministry of Education and Culture 
- total amount of funding (in euros) from the above-mentioned funding organizations: 3553000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
The vision of the IndiViDrug RC for 2011-2013 is to  
 
1. Maintain its position as one of the internationally leading centers in the research of individual 
variability in drug response, in particular due to drug interactions and pharmacogenetics, reaching the 
international cutting edge in specific sectors.  
- The research will be directed at improving patient safety and the results will be clinically applicable 
- The results will improve methods of clinical drug development and will thus be useful to the 
pharmaceutical industry 
- Relevant research findings will be transferred to patent applications 
 
2. Maintain its position as a nationally important center for training doctors and researchers in the field 
of clinical drug research. 
- The doctoral training will meet most of the need of doctorate level researchers and experts in the field 
in the health care system, health authorities and in pharmaceutical industry. 
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Action plan of the RC for 2011-2013 
 
One of the major challenges during the period 2011-2013 is the retirement of Professor Pertti Neuvonen 
in 2011, because his successor is not known. However, he will continue in the RC after his retirement. In 
addition, the leadership of the CDRGS graduate school will be transferred from him to Janne Backman, 
so that all the leadership arrangements of the RC will remain functional during the interregnum period.  
 
The CDRGS will join with other FinPharmaNet graduate schools to form the FinPharma Doctoral Program 
in the beginning of 2012. A total of 9 doctoral student positions of the FinPharma Doctoral Program 
application (under evaluation) have been allocated to the Clinical Drug Research section. In addition, the 
RC will work to even increase its other university and hospital positions that are suitable for doctoral 
students. Thus, the total number of positions for doctoral students will be adequate. In addition, to 
complement the expertise of its present six principal investigators and to strengthen the capacity and 
quality of its research, the RC aims to raise external funding to recruit one or more postdoctoral 
researchers to the team. If necessary, hospital senior positions will be utilised in the recruitment of post-
doctoral researchers. 
 
In research, the RC will maintain its strong focus on variability in pharmacokinetics (metabolism and 
transport), including the significance of drug interactions and pharmacogenetics, and increase its efforts 
on other topics, such as the effects of pregnancy, age and other individual factors on drug response and 
safety. Research will be strengthened by increasing collaboration with international and national clinical 
units and basic research groups, and by effective utilization of sophisticated basic and clinical research 
methods. For example, the RC is planning to update its analytical laboratory equipment with a highly 
sensitive LS/MS/MS system. In addition, advanced information technology and computer intensive 
methods will be exploited, in order to 1) understand the relationship between molecular level findings, 
physiological significance and clinical relevance of variability in drug response, 2) to increase the in vitro 
– in vivo predictability of pharmacokinetic variability, and to increase the usefulness of basic research 
methods and simulations, e.g., for drug development, and 3) to integrate information concerning 
different sources of variability (e.g., drug interactions, pharmacogenetics, age) in order to better 
individualize clinical drug treatment. 
 
In doctoral training, the CDRGS graduate school will remain as the mainstay of the high quality of 
training provided by the RC. The union of CDRGS with the other graduate schools to the FinPharma 
Doctoral Program (FPDP) will strengthen the practices of doctoral training, increase the number and 
quality of postgraduate courses, improve the coordination of resources and to some extent also relieve 
the investigators of administrative tasks. In addition, the RC aims at increasing its supervisor resources 
by increasing the number of its positions (see above), and via collaboration with other groups. The 
purpose is that doctoral student positions can be fully exploited to educate a sufficient number of 
doctorates in clinical drug research. Further, international collaboration in doctoral training will be 
increased, eg by the “Global Research in Paediatrics" program. 
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Janne Backman had the main responsibility for the compilation of the material and he wrote the first 
drafts for the majority of the material. In addition, Pertti Neuvonen and Mikko Niemi made substantial 
contributions to drafting specific sections of the material. The other principal investigators (Kalso, 
Hoppu and Malm) had the possibility to comment the text so that their views could also be expressed in 
the text. The other RC members had the possibility to make suggestions to the contents of the material. 
After the commenting, Backman, Neuvonen and Niemi compiled the final material as joint work. 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
MATERIALS (MAX. 1100 CHARACTERS WITH SPACES). 
IndiViDrug RC
1. Drug interactions
- many previously unknown
adverse drug interactions
- role of CYP2C8 in
pharmacokinetics and
drug interactions
- importance of
mechanism-based inhibition
2. Pharmacogenetics
- importance of transporter
(OATP1B1, BCRP
and P-glycoprotein)
pharmacogenetics for the
pharmacokinetics, safety
and efficacy of statins
and other drugs
3. Pregnancy,
immature body
functions, fragility
- safety of SSRIs
during pregnancy
- population pharmacokinetics
in children
- pharmacokinetics in the
elderly
Figure 1. Main research topics and findings in the three focus areas of the IndiViDrug RC during 2005-2010.
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Figure 2. Positions of trust and administration of the IndiViDrug principal investigators in doctoral training organizations
and scientific societies.
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1 Analysis of publications 
 
- Associated person is one of Kati Marjukka Ahonen, Janne Backman ,  Samuel Israel Fanta ,  Anne Filppula , 
 Tarja Heiskanen ,  Kaarlo Hoppu ,  Johanna Honkalammi , Mika 
Heikki Isohanni ,  Tiina Annikki Jaakkola ,  Lauri Kajosaari ,  Annikka Kalliokoski , 
 Eija Kalso ,  Marjo Karjalainen ,  Tiina Karonen ,  Jenni Eliisa 
Keskitalo ,  Jari Lilja, Heli Malm ,  Pertti Neuvonen ,  Mikko Niemi ,  
Marja Pasanen , Päivi Ruokoniemi ,  Marika Schröder ,  Tuija Tapaninen , 
 Aleksi Tornio ,  Xiaoqiang Xiang ,  
 
                   Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 31 41 21 40 28 24 185 
A2 Review in scientific journal 2 1 5 4 3 4 19 
A3 Contribution to book/other compilations (refereed) 2 6 5 3 16 1 33 
B1 Unrefereed journal article 7 7 5 7 17 8 51 
B2 Contribution to book/other compilations (non-refereed)      1 1 
C2 Edited book, compilation, conference proceeding or special issue of 
journal 
 1  1 2 2 6 
D1 Article in professional journal 4 5 8 1   18 
D2 Article in professional hand or guide book or in a professional data 
system, or text book material 
4 3  3 3 6 19 
I1 Audiovisual materials      1 1 
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2 Listing of publications 
A1 Refereed journal article 
2005 
Alaspää, A, Kuisma, M, Hoppu, K, Neuvonen, PJ 2005, 'Out-of-hospital administration of activated charcoal by emergency medical 
services', Annals of Emergency Medicine, vol 45, no. 2, pp. 207-212. 
Backman, J, Luurila, H, Neuvonen, M, Neuvonen, PJ 2005, 'Rifampin markedly decreases and gemfibrozil increases the plasma 
concentrations of atorvastatin and its metabolites', Clinical Pharmacology and Therapeutics, vol 78, no. 2, pp. 154-167. 
Diav-Citrin, O, Arnon, J, Shechtman, S, Schaefer, C, van Tonningen, M, Clementi, M, De Santis, M, Robert-Gnansia, E, Valti, E, Malm, 
T, Ornoy, A 2005, 'The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.', Alimentary 
Pharmacology & Therapeutics, vol 21, pp. 269-275. 
Fanta, S, Backman, JT, Seikku, P, Holmberg, C, Hoppu, K 2005, 'Cyclosporine A monitoring: how to account for twice and three times 
daily dosing', Pediatric Nephrology, vol 20, no. 5, pp. 591-596. 
Granfors, M, Backman, JT, Laitila, J, Neuvonen, PJ 2005, 'Oral contraceptives containing ethinyl estradiol and gestodene markedly 
increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2', Clinical Pharmacology and 
Therapeutics, vol 78, no. 4, pp. 400-411. 
Hamunen, K, Kalso, E 2005, 'A systematic review of trial methodology, using the placebo groups of randomized controlled trials in 
paediatric postoperative pain', Pain : the journal of the International association for the study of pain, vol 116, pp. 146-158. 
Isohanni, MH, Ahonen, J, Neuvonen, PJ, Olkkola, KT 2005, 'Effect of ciprofloxin on the pharmacokinetics of intravenous lidocaine', 
European Journal of Anaesthesiology, vol 22, no. 10, pp. 795-799. 
Jaakkola, T, Backman, JT, Neuvonen, M, Neuvonen, PJ 2005, 'Effects of gemfibrozil, itraconazole, and their combination on the 
pharmacokinetics of pioglitazone', Clinical Pharmacology and Therapeutics, vol 77, no. 5, pp. 404-414. 
Kajosaari, L, Laitila, J, Neuvonen, PJ, Backman, JT  2005, 'Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates 
and rifampicin', Basic & Clinical Pharmacology & Toxicology, vol 97, no. 4, pp. 249-256. 
Kajosaari, L, Niemi, M, Neuvonen, M, Laitila, J, Neuvonen, PJ, Backman, JT  2005, 'Cyclosporine markedly raises the plasma 
concentrations of repaglinide', Clinical Pharmacology and Therapeutics, vol 78, no. 4, pp. 388-399. 
Kalso, E, Allan, L, Dobrogowski, J, Johnson, M, Krcevski-Skvarc, N, Macfarlane, GJ, Mick, G, Ortolani, S, Perrot, S, Perucho, A, 
Semmons, I, Sörensen, J 2005, 'Do strong opioids have a role in the early management of back pain? Recommendations from a 
European expert panel', Current Medical Research and Opinion, vol 21, no. 11, pp. 1819-1828. 
Kalso, E 2005, 'Improving opioid effectiveness: from ideas to evidence', European journal of pain., vol 9, pp. 131-135. 
Kalso, E 2005, 'Sodium channel blockers in neuropathic pain', Current Pharmaceutical Design, vol 11, pp. 3005-3011. 
Kalso, E 2005, 'Oxycodone', Journal of Pain and Symptom Management, vol 29, no. 5S, pp. S47-56. 
Kivistö, KT, Niemi, M, Schaeffeler, E, Pitkälä, K, Tilvis, R, Fromm, MF, Schwab, M, Lang, F, Eichelbaum, M, Strandberg, T, Srandberg, 
T 2005, 'CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study',  American 
journal of pharmacigenomics., vol 5, pp. 191-195. 
Lilja, J, Raaska, K, Neuvonen, PJ 2005, 'Effects of grapefruit juice on the pharmacokinetics of acebutolol', British Journal of Clinical 
Pharmacology, vol 60, no. 6, pp. 659-663. 
Lilja, J, Laitinen, K, Neuvonen, PJ 2005, 'Effects of grapefruit juice on the absorption of levothyroxine', British Journal of Clinical 
Pharmacology, vol 60, no. 3, pp. 337-341. 
Lilja, J, Backman, JT, Neuvonen, PJ 2005, 'Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in 
healthy subjects', British Journal of Clinical Pharmacology, vol 59, no. 4, pp. 433-439. 
Lilja, J, Raaska, K, Neuvonen, PJ 2005, 'Effects of orange juice on the pharmacokinetics of atenolol', European Journal of Clinical 
Pharmacology, vol 61, no. 5-6, pp. 337-340. 
Lilja, J, Backman, JT, Neuvonen, PJ 2005, 'Effect of itraconazole on the pharmacokinetics of atenolol', Basic & Clinical Pharmacology 
& Toxicology, vol 97, no. 6, pp. 395-398. 
Malm, T, Klaukka, T, Neuvonen, PJ 2005, 'Risks associated with selective serotonin reuptake inhibitors in pregnancy', Obstetrics and 
Gynecology, vol 106, no. 6, pp. 1289-1296. 
Munsterhjelm, E, Munsterhjelm, N, Niemi, T, Ylikorkala, O, Neuvonen, PJ, Rosenberg, PH 2005, 'Dose-dependent inhibition of platelet 
function by acetaminophen in healthy volunteers', Anesthesiology, vol 103, no. 4, pp. 712-717. 
Mustola, ST, Baer, G, Neuvonen, PJ, Toivonen, KJ 2005, 'Requirements of propofol at different end-points without adjuvant and during 
two different steady infusions of remifentanil', Acta Anaesthesiologica Scandinavica, vol 49, no. 2, pp. 215-221. 
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Journal of Emergency Medicine, vol 27, no. 1, pp. 128 e5-6. 
2010 
Ellfolk, M, Malm, T 2010, 'Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs)',  
Reproductive Toxicology, vol 30, no. 2, pp. 249-260. 
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Giacomini, KM, Huang, S, Tweedie, DJ, Benet, LZ, Brouwer, KLR, Chu, X, Dahlin, A, Evers, R, Fischer, V, Hillgren, KM, Hoffmaster, 
KA, Ishikawa, T, Keppler, D, Kim, RB, Lee, CA, Niemi, M, Polli, JW, Sugiyama, Y, Swaan, PW, Ware, JA, Wright, SH, Yee, SW, Zamek-
Gliszczynski, MJ, Zhang, L, International Transporter 2010, 'Membrane transporters in drug development', Nature reviews. Drug 
discovery, vol 9, pp. 215-236. 
Moore, RA, Derry, S, McQuay, HJ, Straube, S, Aldington, D, Wiffen, P, Bell, RF, Kalso, E, Rowbotham, MC, IASP Special Interest Grp 
Systemat 2010, 'Clinical effectiveness: An approach to clinical trial design more relevant to clinical practice, acknowledging the 
importance of individual differences', Pain : the journal of the International association for the study of pain, vol 149, no. 2, pp. 
173-176. 
Neuvonen, PJ 2010, 'Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and 
pharmacogenetics', Current opinion in investigational drugs., vol 11, no. 3, pp. 323-332. 
A3 Contribution to book/other compilations (refereed) 
2005 
Backman, JT, Vuoristo, M 2005, 'Lääkkeiden käyttö maksatautien yhteydessä', Pharmaca Fennica, Lääketuojat, Helsinki, pp. 628-
631. 
Neuvonen, PJ 2005, 'Lääkeaineiden haitalliset yhteisvaikutukset', Pharmaca Fennica 2005 I Tiivistelmä, Lääketietokeskus, Helsinki, 
pp. 587-593. 
2006 
Backman, JT, Vuoristo, M 2006, 'Lääkkeiden käyttö maksatautien yhteydessä', Pharmaca Fennica, Lääketietokeskus, Helsinki , pp. 
628-631. 
Heiskanen, T, Karjalainen, H 2006, 'Nosiseptiivinen kipu ja sen hoito', Anestesiologia ja tehohoito, Duodecim, Helsinki, pp. 866-872. 
Hynynen, M, Takkunen, O, Kurola, J, Kalso, E 2006, 'Anestesian, tehohoidon, ensihoidon ja kivunhoidon järjestely', Anestesiologia ja 
tehohoito, Duodecim, Helsinki, pp. 27-37. 
Kalso, E 2006, 'The placebo effect', The Massachusetts General Hospital Handbook of pain, 3. ed, Philadelphia, Lippincott 
Williams & Wilkins,, pp. 28-33. 
Kalso, E 2006, 'Kipuvastaanotto ja kipuklinikka', Anestesiologia ja tehohoito, Duodecim, Helsinki, pp. 852-858. 
Neuvonen, P 2006, 'Lääkeaineiden haitalliset yhteisvaikutukset', Pharmaca Fennica 2006 I Tiivistelmä, Lääketietokeskus, Helsinki, 
pp. 620-627. 
2007 
Backman, JT, Vuoristo, M 2007, 'Lääkkeiden käyttö maksatautien yhteydessä', Pharmaca Fennica, Lääketietokeskus, Helsinki , pp. 
711-713. 
Neuvonen, PJ 2007, 'Eräitä kliinisen farmakologian peruskysymyksiä', Farmakologia ja toksikologia, Medicina ,, Kuopio, pp. 1007-
1012. 
Neuvonen, PJ 2007, 'Lääkeaineiden haitalliset yhteisvaikutukset', Pharmaca Fennica, Lääketietokeskus, Helsinki, pp. 703-709. 
Neuvonen, PJ 2007, 'Diureetit', Farmakologia ja toksikologia, Medicina ,, Kuopio , pp. 579-589. 
Neuvonen, PJ 2007, 'Lääkkeiden yhteisvaikutukset', Farmakologia ja toksikologia, Medicina ,, Kuopio, pp. 1013-1016. 
2008 
Backman, JT, Vuoristo, M 2008, 'Lääkkeiden käyttö maksatautien yhteydessä', Pharmaca Fennica, Lääketietokeskus, Helsinki, pp. 
553-556. 
Kalso, E 2008, 'Opioids in noncancer pain : Systematic reviews of efficacy and safety – What more is needed? ', in MHKEMR (ed.) , 
Systematic Reviews and Meta-Analyses in Pain , IASP Press . 
Neuvonen, PJ 2008, 'Lääkeaineiden haitalliset yhteisvaikutukset',  Pharmaca Fennica, Lääketietokeskus, Helsinki, pp. 545-551. 
2009 
Backman, JT, Vuoristo, M 2009, 'Lääkkeiden käyttö maksatautien yhteydessä', Pharmaca Fennica. lääkevalmisteet., 
Lääketietokeskus, Helsinki, pp. 589-592. 
Hamunen, K, Kalso, E 2009, 'Vamman ja leikkauksen jälkeinen kipu', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; 
kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 278-294. 
Hamunen, K, Kalso, E 2009, 'Puudutukset ja neuroablatiiviset menetelmät', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli 
Vainio ; kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 221-229. 
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Kalso, E 2009, 'Vanhusten kipu', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; kirjoittajat: Heli Aho ... [et al.]. - 
Helsinki : Duodecim, 2009., pp. 470-476. 
Kalso, E 2009, 'Käytännön opioidihoito', Opioidit. [toimitus: Eija Kalso, Pirkko Paakkari ja Marja Forsell., Lääkelaitos,, [Helsinki], 
pp. 10-19. 
Kalso, E, Kontinen, V 2009, 'Kipu tieteellisen tutkimuksen kohteena', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; 
kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 52-63. 
Kalso, E 2009, 'Kannabinoidit kroonisen kivun hoidossa', Opioidit. [toimitus: Eija Kalso, Pirkko Paakkari ja Marja Forsell., 
Lääkelaitos,, [Helsinki], pp. 25-28. 
Kalso, E 2009, 'Opioidien käyttö pitkäaikaisen, muusta kuin syövästä johtuvan kivun hoidossa: eurooppalaisiin suosituksiin perustuva 
päivitetty ohjeistus', Opioidit. [toimitus: Eija Kalso, Pirkko Paakkari ja Marja Forsell., Lääkelaitos,, [Helsinki], pp. 1-9. 
Kalso, E 2009, 'Opioidivalmisteet', Opioidit. [toimitus: Eija Kalso, Pirkko Paakkari ja Marja Forsell., Lääkelaitos,, [Helsinki], pp. 20-
24. 
Kalso, E, Vainio, A, Haanpää, M 2009, 'Kivunhoitomenetelmien vaikuttavuuden arviointi', Kipu / toimittajat. Eija Kalso, Maija 
Haanpää, Anneli Vainio ; kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 173-180. 
Kalso, E 2009, 'Kivun lääkehoito', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; kirjoittajat: Heli Aho ... [et al.]. - 
Helsinki : Duodecim, 2009., pp. 181-219. 
Kalso, E, Kontinen, V 2009, 'Kivun fysiologia ja mekanismit', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; 
kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 76-103. 
Kalso, E, Elomaa, M, Estlander, A, Granström, V 2009, 'Akuutti ja krooninen kipu', Kipu / toimittajat. Eija Kalso, Maija Haanpää, 
Anneli Vainio ; kirjoittajat: Heli Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 104-116. 
Kalso, E 2009, 'Koulutus', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; kirjoittajat: Heli Aho ... [et al.]. - Helsinki : 
Duodecim, 2009., pp. 535-536. 
Neuvonen, PJ 2009, 'Lääkeaineiden haitalliset yhteisvaikutukset',  Pharmaca Fennica. lääkevalmisteet., Lääketietokeskus, Helsinki, 
pp. 581-587. 
Vainio, A, Kalso, E 2009, 'Syöpätauteihin liittyvä kipu', Kipu / toimittajat. Eija Kalso, Maija Haanpää, Anneli Vainio ; kirjoittajat: Heli 
Aho ... [et al.]. - Helsinki : Duodecim, 2009., pp. 478-506. 
2010 
Kalso, E 2010, 'Drugs that act against opioid tolerance', in PJBRKE O (ed.), Cancer Pain: from Molecules to Suffering , IASP Press . 
B1 Unrefereed journal article 
2005 
Alaspää, A, Kuisma, M, Hoppu, K, Neuvonen, PJ 2005, 'Out-of-hospital activated charcoal: not so fast [reply]', Annals of Emergency 
Medicine, vol 46, no. 3, pp. 299-300. 
Hoppu, K 2005, 'Ajankohtaista; Sienimyrkytykset', Duodecim, vol 121, no. 14, pp. 1518-1519. 
Kalso, E 2005, 'Opioids for persistent non-cancer pain', BMJ : British Medical Journal, vol 330, pp. 156-157. 
Klaukka, T, Idänpään-Heikkilä, JE, Neuvonen, PJ 2005, 'Keskustelu masennuslääkityksen turvallisuudesta jatkuu',  Suomen lääkärilehti 
, vol 60, no. 39, pp. 3874-3876. 
Malm, T 2005, 'Psyykenlääkkeiden käyttö ja turvallisuus raskauden ja imetyksen aikana',  Suomen lääkärilehti , vol 60, no. 10, pp. 
1149-1154. 
Neuvonen, PJ, Tilvis, R 2005, 'Diureetit ovat eturivin verenpainelääkkeitä', Suomen lääkärilehti , vol 60, no. 21, pp. 2348-2351. 
Niemi-Murola, L, Pöyhiä, R, Kalso, E 2005, 'Kivunhoidon opetus lääketieteen peruskoulutuksessa', Suomen lääkärilehti , vol 60, no. 
10, pp. 1181-1184. 
2006 
Autti-Rämö, I, Kivitie-Kallio, S, Ritvanen, A, Malm, T  2006, 'Terveydenhuollon ammattilaisten laaja tuki alkoholista varoittavalle 
merkinnälle: [pääkirjoitus]', Suomen lääkärilehti , vol 61, no. 3, pp. 143. 
Backman, JT, Kajosaari, L, Niemi, M, Neuvonen, PJ 2006, 'Cyclosporine A increases plasma concentrations and effects of repaglinide: 
[letter]', American Journal of Transplantation, vol 6, no. 9, pp. 2221-2222. 
Heiskanen, N, Malm, T, Sankilampi, U, Koivula, I, Heinonen, S 2006, 'Mikrobilääkkeiden käyttö raskauden ja imetyksen aikana: 
suositukset puoltavat tuttua ja turvallista : [katsaus]', Suomen lääkärilehti , vol 61, no. 51-52, pp. 5323-5328. 
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Kalso, E 2006, 'Subanesthetic ketamine for cancer pain and scientific rigor in cancer pain trials: a reply to Jackson et al', Journal of 
Pain and Symptom Management, vol 31, no. 5, pp. 386. 
Kuisma, P, Hoppu, K 2006, 'Lääkitysvirheet Myrkytystietokeskuksen näkökulmasta', TABU : lääkeinformaatiota Lääkelaitokselta, vol 
14, no. 4, pp. 8-10. 
Myllärniemi, M, Koistinen, H, Hoppu, K, Lötjönen, J, Kuisma, M, Varpula, M, Pohjola-Sintonen, S 2006, 'Hydroksikobalamiini 
palokaasujen aiheuttaman syanidimyrkytyksen hoidossa: [tapausselostus]', Duodecim, vol 122, no. 9, pp. 1099-1103. 
Niemi, M 2006, 'Farmakogenetiikka ja yksilöllinen lääkehoito [pääkirjoitus]', Suomen lääkärilehti , vol 2006/61, pp. 1079. 
2007 
Hoppu, K 2007, 'Parempia lääkkeitä lapsille', Duodecim, vol 123, no. 16, pp. 1905-1907. 
Kalso, E 2007, 'How different is oxycodone from morphine?: [editorial]', Pain : the journal of the International association for the 
study of pain, vol 132, no. 3, pp. 227-228. 
Kontinen, VK, Kalso, E 2007, 'Of mice and men: what can we predict from the effects of morphine in a mouse model of bone cancer? : 
[editorial]', Pain : the journal of the International association for the study of pain, vol 132, no. 1-2, pp. 5-7. 
Laine, P, Hoppu, K 2007, 'Gamma, lakka ja Internet-huumeet', Duodecim, vol 123, no. 18, pp. 2159-2160. 
Lemberg, K, Korpi, E, Siiskonen, A, Yli-Kauhaluoma, J, Kontinen, VK, Viljakka, K, Kalso, E, Korpi, ER 2007, 'Oxycodone's mechanism 
of action and potency differences after spinal and systemic routes of administration: [reply]',  Anesthesiology, vol 106, no. 5, pp. 1064-
1065. 
2008 
Hoppu, K 2008, 'Parempia lääkkeitä luvassa lapsille', Kipuviesti : Suomen kivuntutkimusyhdistyksen jäsenlehti., no. 2, pp. 27-29. 
Hoppu, K 2008, 'Lastenlääkkeiden uusi aika: [katsaus]', Dosis, vol 24, no. 1, pp. 7-12. 
Hoppu, K 2008, 'Paediatric clinical pharmacology: at the beginning of a new era',  European Journal of Clinical Pharmacology, vol 64, 
no. 2, pp. 201-205. 
Kalso, E 2008, 'Global year on cancer pain: [editorial]', Pain : the journal of the International association for the study of pain, vol 
140, no. 2, pp. 247-248. 
Malm, T, Nurminen, M 2008, 'Isotretinoiinia käytetään edelleen raskauden aikana: [lääkeinfo]', Suomen lääkärilehti , vol 63, no. 46, pp. 
4028-4030. 
Ranki-Pesonen, M, Niemi, M 2008, 'Farmakogeneettinen tieto avuksi yksilöllisten lääkeannosten määritykseen', Duodecim, vol 124, no. 
11, pp. 1269-1271. 
WHO Expert Committee, Coelho, H, Cranswick, N, Gilani, A, Gray, A, Gupta, U, Helali, A, Hoppu, K, Irs, A, Kazembe, P, Mehta, D, 
Reidenberg, M, Suryawati, S, Walters, S, Pedersen, H, Chongtrakul, P, Zhiping, L, Nakamura, H, Robertson, J, Hill, S, Hogerzeil, H, 
Ondari, C, Zisovska, E, Davies, E, Kearns, G, Mattison, D, Terlouw, D 2008, 'The selection and use of essential medicines', World 
Health Organization technical report series, no. 950, pp. backcover,vii-174. 
2009 
Hoppu, K, Kuitunen, T, Kuisma, P 2009, 'Myrkytystietokeskukseen tulee yhä enemmän kyselyjä lääkitysvirheistä terveydenhuollossa: 
[lääkeinfo]', Suomen lääkärilehti , vol 64, no. 24, pp. 2208-2211. 
Hoppu, K 2009, 'Can we get the necessary clinical trials in children and avoid the unnecessary ones?: [editorial]', European Journal of 
Clinical Pharmacology, vol 65, no. 8, pp. 747-748. 
Hoppu, K 2009, 'IUPHAR Clinical Division activities at the centre of global action for Better Medicines for Children', Pharmacology 
International, vol 72, pp. 34-35. 
Jaakkola, T, Backman, JT, Palva, E, Neuvonen, P 2009, 'Siprofloksasiini ja fluvoksamiini voivat aiheuttaa vaarallisia CYP1A2 - välitteisiä 
yhteisvaikutuksia: [lääkeinfo]', Suomen lääkärilehti , vol 64, no. 45, pp. 3866-3869. 
Kalliokoski, A, Idänpään-Heikkilä, JE 2009, 'Haittavaikutuksista käyttöaiheiksi', Suomen lääkärilehti , vol 2009, no. 34, pp. 2687-2690. 
Kalliokoski, A, Airola, K, Huupponen, R 2009, 'Monoklonaaliset vasta-aineet tulossa yhä useamman sairauden hoitoon',  Suomen 
lääkärilehti , vol 2009, no. 51-52, pp. 4485-4490. 
Kalliokoski, A, Idänpään-Heikkilä, JE 2009, 'Dketropropoksifeeni poistuu - mitä tilalle', Suomen lääkärilehti , vol 2009, no. 36, pp. 2905-
2907. 
Kalso, E 2009, 'Kyllä se kipu hoidetaan - rauhoittukaa: lääkärien näkemykset syöpäkivun hoidosta : [pääkirjoitus]', Suomen lääkärilehti 
, vol 64, no. 41, pp. 3397. 
Laitinen, K, Sane, T, Fanta, SI 2009, 'Miksi mikään tyroksiiniannos ei tunnu riittävän?: [tapausselostus]', Duodecim, vol 125, no. 13, pp. 
1427-1429. 
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Malm, T 2009, 'Isän kautta välittyvä teratogeneesi: aiheetonta pelkoa syytä välttää : [lääkeinfo]', Suomen lääkärilehti , vol 64, no. 11, 
pp. 1036-1037. 
Neuvonen, PJ 2009, 'Nuoren tutkijan palkinto Mikko Niemelle: [palkinnot]', Duodecim, vol 125, no. 22, pp. 2479-2480. 
Niemi, M 2009, 'Geenimuunnos statiinien aiheuttaman myopatian taustalla: [pääkirjoitus]', Duodecim, vol 125, no. 3, pp. 241-243. 
Niemi, M, Kalliokoski, A 2009, 'Farmakogenetiikkaa käytännön lääkärille: [lääkeinfo]', Suomen lääkärilehti , vol 64, no. 41, pp. 3443-
3446. 
Reenilä, I, Neuvonen, P 2009, 'Joint Meeting of the FinPharmaNet graduate schools, August 13-14, University of Helsinki',  Dosis, vol 
25, no. 3, pp. 145. 
Reenilä, I, Neuvonen, P 2009, 'FinPharmaNet-verkoston tutkijakoulutapaaminen Helsingin yliopistossa 13.-14.8.2009', Dosis, vol 25, 
no. 3, pp. 144. 
Siiskonen, E, Hamunen, K, Niemi-Murola, L, Kalso, E 2009, 'Potilastapauksista oppia syöpäkivun hoidosta: [kivun hoito]',  Suomen 
lääkärilehti , vol 64, no. 41, pp. 3453-3458. 
WHO Expert Committee, Dodoo, A, Fernandopulle, R, Gray, A, Henkens, M, Hoppu, K, Kearns, G, Delgado, E, Reidenberg, M, 
Wannmacher, L, Zaidi, A, Batmanabane, G, Hua, D, How, C, Zisovska, E, Kozarewicz, P, Pedersen, H, Wolman, Y, Fauveau, V, 
Doedens, W, Hogerzeil, H, Ondari, C, Hill, S, Ridge, A, Akmal, R 2009, 'The selection and use of essential medicines', World Health 
Organization technical report series, no. 958, pp. 1-242, backcover. 
2010 
Gordh, TE, Jensen, TS, Kalso, E 2010, 'Reporting of Trials of Gabapentin', New England Journal of Medicine, vol 362, pp. 1641. 
Heiskanen, T, Backman, J 2010, 'Tramadoli kipulääkkeenä: hyödyt ja haitat on punnittava potilaskohtaisesti.', Suomen lääkärilehti , vol 
2010, pp. 2701-2705. 
Hoppu, K, Pakkala, S 2010, 'Lastenlääketutkimusten avaimet yliopistosairaaloilla', Suomen lääkärilehti , vol 65, no. 47, pp. 3858. 
Kalliokoski, A, Martikainen, JE, Saastamoinen, LK 2010, 'Tyypin 2 diabeteksen lääkehoito vuosina 2004-2009',  Suomen lääkärilehti , 
vol 2010, no. 26, pp. 2411-2413. 
Kalliokoski, A, Martikainen, JE, Saastamoinen, LK, Kruuti, J, Koivisto, P 2010, 'Sairausvakuutuksesta korvatun reseptin kustannus 
pieneni vuonna 2009', Suomen lääkärilehti , vol 2009, no. 20, pp. 1847-1850. 
Kalso, E, Hearn, L, Williams, ACDC 2010, 'Reducing the risk of opioid misuse in persistent pain: Commentary on Jamison et al.', Pain : 
the journal of the International association for the study of pain, vol 150, pp. 375-376. 
Lilja, J 2010, 'Hedelmämehut voivat aiheuttaa yhteisvaikutuksia lääkehoidossa', Suomen lääkärilehti , vol 65, pp. 1237-1239. 
Malm, T 2010, 'Parasetamoli ja tulehduskipulääkkeet raskauden aikana - ei aihetta muuttaa hoitokäytäntöä',  Suomen lääkärilehti , no. 
46, pp. 3808-3809. 
B2 Contribution to book/other compilations (non-refereed) 
2010 
Backman, J, Arkkila, P 2010, 'Lääkkeiden käyttö maksatautien yhteydessä.', 2010 Pharmaca Fennica: Lääkevalmisteet. Osa I, 
Lääketietokeskus, pp. 672-675. 
C2 Edited book, compilation, conference proceeding or special issue of journal 
2006 
Flor, H, Kalso, E, Dostrovsky, O 2006, Proceedings on the 11th World Congress on Pain, Progress in Research and Management, 
vol. 25, IASP Press . 
2008 
McQuay, H, Kalso, E, Moore, R 2008, Systematic Reviews and Meta-Analyses in Pain, IASP Press . 
2009 
Kalso, E, Haanpää, M, Vainio, A (eds) 2009, Kipu, 3. uud. p edn, Helsinki, 260. 
Kalso, E, Paakkari, P, Forsell, M (eds) 2009, Opioidit: pitkäkestoisessa kivussa, 2. uud. p edn, Lääkelaitos, [Helsinki]. 
2010 
Paice, J, Bell, R, Kalso, E, Soyanwo, O 2010, Cancer pain: from molecules to suffering, IASP Press . 
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Stannard, C, Kalso, E, Ballantyne , J (eds) 2010, Evidence-Based Chronic Pain Management,  Wiley-Blackwell. 
D1 Article in professional journal 
2005 
Kalliokoski, A 2005, 'Raskauden ehkäisy injektiovalmisteella', TABU : lääkeinformaatiota Lääkelaitokselta, no. 5, pp. 20. 
Kalliokoski, A 2005, 'Kommentti artikkeliin "Oma lääkehaittahavaintoni: Vieroitusoireita venlafaksiinin käytön lopettamisen jälkeen"',  
TABU : lääkeinformaatiota Lääkelaitokselta, no. 4, pp. 13. 
Kalliokoski, A 2005, 'Tramal tippojen annostus annospumppupulloista', TABU : lääkeinformaatiota Lääkelaitokselta, no. 4, pp. 9. 
Merivuori, T, Kalliokoski, A 2005, 'Nitrofurantoiinii ja keuhkohaitat', TABU : lääkeinformaatiota Lääkelaitokselta, no. 5, pp. 21-23. 
2006 
Kalliokoski, A, Sommarberg, L 2006, 'Masennuslääkkeiden haitoista', TABU : lääkeinformaatiota Lääkelaitokselta, no. 4, pp. 17. 
Kalliokoski, A, Sommarberg, L, Forsell, M 2006, 'Haittavaikutusrekisterin vuosi 2005 - uutta ja vanhaa', TABU : lääkeinformaatiota 
Lääkelaitokselta, no. 2, pp. 13-16. 
Kalliokoski, A 2006, 'Keftriaksoni ja sappirakon oireilu', TABU : lääkeinformaatiota Lääkelaitokselta, no. 5, pp. 16. 
Kalliokoski, A 2006, 'Mikonatsoligeelin käyttöä tulee välttää varfariinihoitoa saaville potilaille', TABU : lääkeinformaatiota 
Lääkelaitokselta, no. 6, pp. 20. 
Kalliokoski, A 2006, 'Kommentti artikkeliin "Oma lääkehaittahavaintoni: Telitromysiini ja valoihottuma', TABU : lääkeinformaatiota 
Lääkelaitokselta, no. 4, pp. 16. 
2007 
Backman, J, Kalliokoski, A, Raaska, KTJ 2007, 'Käytännön farmakogenetiikkaa', TABU : lääkeinformaatiota Lääkelaitokselta , no. 6, 
pp. 14-19. 
Kalliokoski, A, Sommarberg , L, Forsell, M 2007, 'Haittavaikutukset lapsilla', TABU : lääkeinformaatiota Lääkelaitokselta , no. 4, pp. 
13-15. 
Kalliokoski, A 2007, 'Desmopressiinin käyttöaiheen poisto', TABU : lääkeinformaatiota Lääkelaitokselta, no. 3, pp. 19. 
Kalliokoski, A 2007, 'Omalitsumabi', TABU : lääkeinformaatiota Lääkelaitokselta, no. 4, pp. 11-12. 
Kalliokoski, A 2007, 'Haittavaikutustietojen tulkinnasta', TABU : lääkeinformaatiota Lääkelaitokselta, no. 3, pp. 12. 
Kalliokoski, A, Sommarberg, L, Forsell, M 2007, 'Haittavaikutukset ikäihmisillä', TABU : lääkeinformaatiota Lääkelaitokselta, no. 5, 
pp. 13-17. 
Kalliokoski, A, Sommarberg, L 2007, 'Haittavuosi 2006', TABU : lääkeinformaatiota Lääkelaitokselta, no. 2, pp. 12-14. 
Tjäderhane, L, Kalliokoski, A 2007, 'Artikaiinipuudutteet ja tuntohäiriöt', TABU : lääkeinformaatiota Lääkelaitokselta, vol 15, no. 6, pp. 
24-26. 
2008 
Lilja, J 2008, 'Ruuan vaikutus lääkeaineiden farmakokinetiikkaan', TABU : lääkeinformaatiota Lääkelaitokselta, vol 16, no. 6, pp. 17-
19. 
D2 Article in professional hand or guide book or in a professional data system, or text book 
material 
2005 
Hoppu, K 2005, 'Sienien aiheuttamat myrkytykset', in E Elonen, M Mäkijärvi, L Voipio-Pulkki, M Vuoristo (eds), Akuuttihoito-opas, 
10.uud.p. edn, Kustannus Oy Duodecim, pp. 503-504. 
Hoppu, K 2005, 'Valkokärpässienen ja kavalakärpässienen aiheuttama myrkytys', in E Elonen, M Mäkijärvi, L Voipio-Pulkki, M Vuoristo 
(eds), Akuuttihoito-opas, 10.uud.p. edn, Kustannus Oy Duodecim, pp. 504-505. 
Hoppu, K 2005, 'Puna-, rusko- ja pantterikärpässienen aiheuttama myrkytys', in E Elonen, M Mäkijärvi, L Voipio-Pulkki, M Vuoristo 
(eds), Akuuttihoito-opas, 10.uud.p. edn, Kustannus Oy Duodecim, pp. 506-507. 
Hoppu, K 2005, 'Suippumyrkkyseitikin aiheuttama myrkytys', in E Elonen, M Mäkijärvi, L Voipio-Pulkki, M Vuoristo (eds) , Akuuttihoito-
opas, 10.uud.p. edn, Kustannus Oy Duodecim, pp. 505-506. 
2006 
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Hoppu, K 2006, 'Lasten lääketutkimukset', in S Aaltonen, A Saarinen (eds), Lääkkeet ja Terveys, Lääketietokeskus, pp. 17-19. 
Hoppu, K 2006, 'Lasten myrkytykset', in I Kunnamo (ed.), Lääkärin käsikirja, Kustannus Oy Duodecim, pp. 1001-1002. 
Saint Raymond, A, Hoppu, K 2006, 'European regulation and the EMEA', in E Jacqz-Aigrain, I Choonara (eds), Paediatric Clinical 
Pharmacology, pp. 19-24. 
2008 
Hoppu, K 2008, 'Huumeyliannospotilaan hoito', in E Elonen, M Mäkijärvi, M Vuoristo (eds), Akuuttihoito-opas, 12 uud.p. edn, 
Kustannus Oy Duodecim, pp. 513-516. 
Hoppu, K 2008, 'Huumeyliannospotilaan tunnistaminen ja huumemyrkytyksen diagnostiikka', in E Elonen, M Mäkijärvi, M Vuoristo (eds) , 
Akuuttihoito-opas, 12.uud.p. edn, Kustannus Oy Duodecim, pp. 510-513. 
Reid, C, Kalso, E 2008, 'Oxycodone', in K Forbes (ed.), Oxford Pain management Library - Opioids in cancer Pain, Oxford 
University Press. 
2009 
Hoppu, K, Kuusela, A 2009, 'Lasten ja nuorten etanoli- ja huumemyrkytysten hoito', in M Korppi, L Kröger, H Rantala (eds), 
Lastentautien päivystyskirja, Kustannus Oy Duodecim, pp. 25-28. 
Hoppu, K, Pajarre-Sorsa, S 2009, 'Myrkytysten hoito', in E Ruokonen, I Koivula, I Parviainen, J Perttilä (eds), Akuuttihoidon lääkkeet 
ja niiden käyttö, Kustannus Oy Duodecim, pp. 175-202. 
Hoppu, K, Kuusela, A 2009, 'Pikkulasten myrkytystapahtumien hoito', in M Korppi, L Kröger, H Rantala (eds), Lastentautien 
päivystyskirja, Kustannus Oy Duodecim, pp. 22-25. 
2010 
Hoppu, K 2010, 'Myrkytykset', in J Rajantie, J Mertsola, M Heikinheimo (eds), Lastentaudit, 4.uud.p. edn, Kustannus Oy Duodecim, 
pp. 526-529. 
Hoppu, K 2010, 'Lasten lääkehoidon erityispiirteitä', in J Rajantie, J Mertsola, M Heikinheimo (eds), Lastentaudit, Kustannus Oy 
Duodecim, pp. 26-27. 
Hoppu, K, Hill, S 2010, 'Providing global access to essential medicines for children - the WHO Better Medicines for Children 
programme', in K Rose, J van den Anker (eds), Guide to Paediatric Drug Development and Clinical Research, S. Karger, pp. 40-45. 
Kalso, E, Salomäki, T 2010, 'Management of pain in a trauma patient', Traumatology, 7th ed. edn, Kandidaattikustannus. 
Lilja, J, Ylitalo, P, Neuvonen, P 2010, 'Lääkeaineet ja myrkytykset', in O Niemelä, K Pulkki (eds), Laboratoriolääketiede; Kliininen 
kemia ja hematologia, 3.uud.p. edn, Kandidaattikustannus, pp. 339-349. 
Neuvonen, P 2010, 'Lääkeaineiden haitalliset yhteisvaikutukset', Pharmaca Fennica 2010 osa 1 , Lääketietokeskus, pp. 664-670. 
I1 Audiovisual materials 
2010 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Kati Marjukka Ahonen, Janne Backman ,  Samuel Israel Fanta ,  Anne Filppula , 
 Tarja Heiskanen ,  Kaarlo Hoppu ,  Johanna Honkalammi , Mika 
Heikki Isohanni ,  Tiina Annikki Jaakkola ,  Lauri Kajosaari ,  Annikka Kalliokoski , 
 Eija Kalso ,  Marjo Karjalainen ,  Tiina Karonen ,  Jenni Eliisa 
Keskitalo ,  Jari Lilja, Heli Malm ,  Pertti Neuvonen ,  Mikko Niemi ,  
Marja Pasanen , Päivi Ruokoniemi ,  Marika Schröder ,  Tuija Tapaninen , 
 Aleksi Tornio ,  Xiaoqiang Xiang ,  
 
   
Activity type 
Supervisor or co-supervisor of doctoral thesis 56 
Prizes and awards 13 
Editor of research journal 19 
Editor of research anthology/collection/conference proceedings 5 
Peer review of manuscripts 81 
Editor of special theme number 3 
Assessment of candidates for academic posts 6 
Membership or other role in research network 12 
Membership or other role in national/international committee, council, board 29 
Membership or other role in public Finnish or international organization 34 
Membership or other role of body in private company/organisation 3 
Participation in interview for written media 30 
Participation in radio programme 4 
Participation in TV programme 4 
Participation in interview for web based media 22 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Janne Backman ,  
Supervision of PhD thesis of Lauri Kajosaari, MD, Janne Backman, 2002  15.12.2005, Finland 
Supervision of PhD thesis of Marika Granfors, MD, Janne Backman, 2002  16.12.2005, Finland 
Mentoring of PhD thesis of Marja Pasanen, Janne Backman, 2003  2008, Finland 
Supervision of PhD thesis of Aleksi Tornio, MD, Janne Backman, 2003  29.08.2008, Finland 
Supervision of PhD thesis of Marjo Karjalainen, MD, Janne Backman, 2003  15.08.2008, Finland 
Supervision of PhD thesis of Tiina Jaakkola, MD, Janne Backman, 2003  24.08.2007, Finland 
Mentoring of PhD thesis of Annikka Kalliokoski, Janne Backman, 2005  2008, Finland 
Supervision of PhD Thesis of Samuel Fanta, MD, Janne Backman, 2005  13.11.2009 
Mentoring of PhD thesis of Jenni Keskitalo, Janne Backman, 2008  …, Finland 
Mentoring of PhD thesis of Tuija Tapaninen, Janne Backman, 2008  …, Finland 
Mentoring of PhD thesis of Xiaoqiang Xiang, Janne Backman, 2008  …, Finland 
Supervision of PhD thesis of Johanna Honkalammi, MD, Janne Backman, 2008  …, Finland 
Supervision of PhD thesis of Tiina Karonen, MD, Janne Backman, 2008  …, Finland 
Supervision of PhD thesis of Anne Filppula, MSc (pharmacy), Janne Backman, 2010  …, Finland 
Kaarlo Hoppu ,  
Participation in thesis supervision, Kaarlo Hoppu, 2008, Finland 
Participation in thesis supervision, Kaarlo Hoppu, 2009, Finland 
Eija Kalso ,  
Supervision of doctoral thesis, Eija Kalso, 01.01.2001  03.11.2006, Norway 
Supervision of doctoral dissertation, Eija Kalso, 2002  04.12.2008, Finland 
Supervision of doctoral thesis, Eija Kalso, 2004  04.12.2009, Finland 
Supervision of doctoral thesis, Eija Kalso, 2004  2012, Finland 
Supervision of doctoral thesis, Eija Kalso, 2006  2012, Finland 
Supervision of doctoral thesis, Eija Kalso, 2007  2012, Finland 
Supervision of doctoral thesis, Eija Kalso, 2009  2012, Finland 
Pertti Neuvonen ,  
Supervision of PhD thesis of Mika Isohanni, MD, Pertti Neuvonen, 1996  28.11.2009 
Supervision of PhD thesis of Heli Malm, MD, Pertti Neuvonen, 2000  20.12.2005 
Mentoring, PhD thesis of Mia Koskinen, MD, Pertti Neuvonen, 2001  2006 
Supervision of PhD thesis of Lauri Kajosaari, MD, Pertti Neuvonen, 2002  15.12.2006 
Supervision of PhD thesis of Marika Granfors, MD, Pertti Neuvonen, 2002  16.12.2005 
Supervision of PhD thesis of Aleksi Tornio, MD, Pertti Neuvonen, 2003  29.08.2008 
Supervision of PhD thesis of Marja Pasanen, MD, Pertti Neuvonen, 2003  19.12.2008 
Supervision of PhD thesis of Marjo Karjalainen, MD, Pertti Neuvonen, 2003  2008 
Supervision of PhD thesis of Tiina Jaakkola, MD, Pertti Neuvonen, 2003  24.08.2007 
Mentoring, PhD thesis of Teijo Saari, MD, Pertti Neuvonen, 2004  2007 
Mentoring, PhD thesis of Ville-Veikko Hynninen, MD, Pertti Neuvonen, 2004  2008 
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Supervision of PhD thesis of Annikka Kalliokoski, MD, Pertti Neuvonen, 2005  05.12.2008 
Mentoring, PhD thesis of Tuija Nieminen MD, Pertti Neuvonen, 2007  2010 
Mentoring, PhD thesis of Antti Liukas, MD, Pertti Neuvonen, 2008  2011 
Mentoring, PhD thesis of Juha Grönlund, MD, Pertti Neuvonen, 2008  2011 
Supervision of PhD thesis of Jenni Keskitalo, MD, Pertti Neuvonen, 2008  … 
Supervision of PhD thesis of Johanna Honkalammi, MD, Pertti Neuvonen, 2008  … 
Supervision of PhD thesis of Tiina Karonen, MD, Pertti Neuvonen, 2008  … 
Supervision of PhD thesis of Tuija Tapaninen, MD, Pertti Neuvonen, 2008  … 
Supervision of PhD thesis of Xiaoqiang Xiang, MSc (pharmacy), Pertti Neuvonen, 2008  … 
Mentoring, PhD thesis of Marko Peltoniemi, MD, Pertti Neuvonen, 2009  2011 
Supervision of PhD thesis of Anne Filppula, MSc (pharmacy), Pertti Neuvonen, 2010  … 
Mikko Niemi ,  
Mentoring of PhD thesis of Lauri Kajosaari, Mikko Niemi, 2002  2005, Finland 
Mentoring of PhD thesis of Aleksi Tornio, Mikko Niemi, 2003  2008, Finland 
Mentoring of PhD thesis of Tiina Jaakkola, Mikko Niemi, 2003  2008, Finland 
Supervision of PhD thesis of Marja Pasanen, Mikko Niemi, 2003  2008, Finland 
Mentoring of PhD thesis of Samuel Fanta, Mikko Niemi, 2005  2009, Finland 
Supervision of PhD thesis of Annikka Kalliokoski, Mikko Niemi, 2005  2008, Finland 
Mentoring of PhD thesis of Johanna Honkalammi, Mikko Niemi, 2008  …, Finland 
Mentoring of PhD thesis of Tiina Karonen, Mikko Niemi, 2008  …, Finland 
Supervision of PhD thesis of Jenni Keskitalo, Mikko Niemi, 2008  …, Finland 
Supervision of PhD thesis of Tuija Tapaninen, Mikko Niemi, 2008  …, Finland 
Supervision of PhD thesis of Xiaoqiang Xiang, Mikko Niemi, 2008  …, Finland 
Prizes and awards 
Samuel Israel Fanta ,  
Finnish Society for Clinical Pharmacology and Therapeutics, Thesis award 2009, Samuel Israel Fanta, 2009, Finland 
Tarja Heiskanen ,  
Suomen Lääkärilehti, vuoden kirjoitus 2009, Tarja Heiskanen, 2009  …, Finland 
Eija Kalso ,  
Konrad ReijoWaara Prize, Eija Kalso, 12.2007 
Finska Läkaresällskapet: best textbook in Finnish, Eija Kalso, 01.2010 
Member of the Finnish Academy of Sciences, Eija Kalso, 04.2010 
Pertti Neuvonen ,  
Invited Member of the Finnish Academy Science and Letters (Academia Scientiarum Fennica, Suomalainen Tiedeakatemia), Pertti 
Neuvonen, 1998  …, Finland 
Highly Cited Researcher (pharmacology), Thomson Reuters, ISI Web of Knowledge, Pertti Neuvonen, 2005  … 
Mikko Niemi ,  
Young Investigator Award, Mikko Niemi, 11.2009, Finland 
Anders Jahre Prize for Young Scientists, Mikko Niemi, 10.2010, Norway 
Marja Pasanen ,  
Finnish Pharmacologial Society, Doctoral thesis award 2009, Marja Pasanen, 2009, Finland 
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Finnish Society for Clinical Pharmacology and Therapeutics, Doctoral thesis award 2009, Marja Pasanen, 2009, Finland 
Finnish Medical Journal, Doctoral thesis award 2010, Marja Pasanen, 2010, Finland 
University of Helsinki, Doctoral thesis award 2010, Marja Pasanen, 2010, Finland 
Editor of research journal 
Kaarlo Hoppu ,  
Editor of rearch journal, Kaarlo Hoppu, 2004  2008 
Editor of rearch journal, Kaarlo Hoppu, 2005  … 
Editor of research journal, Kaarlo Hoppu, 2007  … 
Annikka Kalliokoski ,  
Suomen Lääkärilehti Lääkeinfo-palsta, Annikka Kalliokoski, 01.05.2009  … 
Sic!-Lääketietolehti, Annikka Kalliokoski, 01.09.2010  … 
Eija Kalso ,  
European Journal of Pain, Eija Kalso, 01.01.1997  … 
The Journal of Pain, Eija Kalso, 01.01.1997  31.12.2007 
Pain, Eija Kalso, 01.01.2004  31.12.2011 
Pertti Neuvonen ,  
Clinical Pharmacokinetics, Editorial Board member, Pertti Neuvonen, 2000  2011 
European Journal of Clinical Pharmacology, Advisory Editor, Pertti Neuvonen, 2000  2011, Germany 
International Journal of Clinical Pharmacology and Therapeutics, Editorial Board member, Pertti Neuvonen, 2000  2011 
Current Diabetes Reviews, Editorial Advisory Board, Pertti Neuvonen, 2005  2011 
Mikko Niemi ,  
Pharmacogenetics &amp; Genomics, Editorial Board Member, Mikko Niemi, 2007  … 
Pharmacogenomics, Editorial Board Member, Mikko Niemi, 2008  … 
Expert Review of Clinical Pharmacology, Editorial Board Member, Mikko Niemi, 2009  … 
Basic &amp; Clinical Pharmacology &amp; Toxicology, Editorial Board Member, Mikko Niemi, 2010  … 
European Journal of Clinical Pharmacology, Editorial Board Member, Mikko Niemi, 2010  … 
Frontiers in Drug Metabolism and Transport, Editorial Board Member, Mikko Niemi, 2010  … 
Frontiers in Pharmacogenetics, Associate Editor, Mikko Niemi, 2010  … 
Editor of research anthology/collection/conference proceedings 
Janne Backman ,  
The Textbook "Kliininen farmakologia ja lääkehoito" (Clinical Pharmacology and Drug Therapy, 1062 pages), Editorial Board Member, 
Janne Backman, 01.01.2008  15.01.2011, Finland 
Eija Kalso ,  
Proceedings of the 11th World Congress on Pain, Eija Kalso, 01.03.2005  31.12.2005, United States 
Systematic Reviews in Pain Research: Methodology Refined, Eija Kalso, 01.01.2006  31.05.2008 
Cancer Pain: From Molecules to Suffering, Eija Kalso, 01.12.2008  31.03.2010 
Pertti Neuvonen ,  
Chairman and member of Editorial Board of the textbook Kliininen farmakologia ja lääkehoito (Clinical Pharmacology and Drug Therapy, 
1062 pages), Pertti Neuvonen, 01.01.2008  15.01.2011, Finland 
 
 
 
IndiViDrug/Backman 
 
 
5 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010 
 
 
Peer review of manuscripts 
Janne Backman ,  
Clincal Drug Investigation, Reviewer (1-2 articles annually), Janne Backman, 01.06.2001  … 
CNS Drugs, Reviewer (1-2 articles annually), Janne Backman, 01.01.2002  01.2006 
Pharmacogenetics and Genomics, Reviewer (occasionally), Janne Backman, 01.01.2002  … 
British Journal of Clinical Pharmacology, Reviewer (1-3 articles annually), Janne Backman, 01.01.2003  … 
European Journal of Clinical Pharmacology, Reviewer (2-7 articles annually), Janne Backman, 01.01.2003  … 
New England Journal of Medicine, Reviewer (1 article annually), Janne Backman, 01.01.2004  … 
Pain, Reviewer (1-2 articles annually), Janne Backman, 01.01.2004  … 
Basic and Clinical Pharmacology and Toxicology (1-4 articles annually), Janne Backman, 01.01.2005  … 
Clinical Pharmacology and Therapeutics, Reviewer (2-4 articles annually), Janne Backman, 01.01.2005  … 
Clinical Pharmacokinetics, Reviewer (1-2 articles annually), Janne Backman, 01.01.2006  … 
Epilepsia, Reviewer (1-2 articles annually), Janne Backman, 01.01.2006  … 
Food and Chemical Toxicology, Reviewer (1-2 articles annually), Janne Backman, 01.01.2006  … 
Drug Metabolism and Disposition, Reviewer (2-6 articles annually), Janne Backman, 15.02.2007  … 
Drug Safety, Reviewer, Janne Backman, 15.02.2007  12.2007 
European Journal of Pharmaceutical Sciences, Reviewer (1-2 articles annually), Janne Backman, 15.02.2007  … 
Expert Opinion on Drug Metabolism &amp; Toxicology, Expert Opinion on Drug Metabolism &amp; Toxicology, Janne Backman, 
15.02.2007  2008 
Pharmaceutical Research, Reviewer, Janne Backman, 15.02.2007  2008 
Naunyn Schmiedebergs Arch Pharmacol, Reviewer, Janne Backman, 31.12.2008  2009, Germany 
Annals of Medicine, Reviewer (1-2 articles annually), Janne Backman, 19.01.2009  …, Finland 
Chemical Research in Toxicology, Reviewer (1-2 articles annually), Janne Backman, 19.04.2009  …, United States 
Journal of Clinical Pharmacology, Reviewer (1-2 articles annually), Janne Backman, 07.10.2009  …, United States 
Pharmacogenomics, Reviewer (1-2 articles annually), Janne Backman, 19.05.2009  … 
Thrombosis Research, Reviewer (1-2 articles annually), Janne Backman, 13.08.2009  … 
Samuel Israel Fanta ,  
American Journal of Clinical Pharmacology, Samuel Israel Fanta, 2010  … 
Tarja Heiskanen ,  
Duodecim, Tarja Heiskanen, 2008  …, Finland 
Pain, Tarja Heiskanen, 2009  … 
Suomen Lääkärilehti, Tarja Heiskanen, 2009  …, Finland 
Kaarlo Hoppu ,  
Acta Pediatrica, Kaarlo Hoppu, 2005  … 
Archives of diseases in Childhood, Kaarlo Hoppu, 2005  … 
British Journal of Clinical Pharmacology, Kaarlo Hoppu, 2005  … 
Clinical Pharmacology and Therapeutics, Kaarlo Hoppu, 2005  … 
Clinical Toxicology, Kaarlo Hoppu, 2005  … 
Duodecim, Kaarlo Hoppu, 2005  …, Finland 
European Journal of Clinical Pharmacology, Kaarlo Hoppu, 2005  … 
Indian Journal of Medical Research, Kaarlo Hoppu, 2005  … 
International Journal of Clinical Pharmacology and Therapeutics, Kaarlo Hoppu, 2005  … 
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Journal of Pediatrics, Kaarlo Hoppu, 2005  … 
Lancet, Kaarlo Hoppu, 2005  … 
Pediatries, Kaarlo Hoppu, 2005  … 
Suomen Lääkärilehti, Kaarlo Hoppu, 2005  …, Finland 
Eija Kalso ,  
Anesthesia and Analgesia, Eija Kalso, 01.01.2000  31.12.2011, United States 
British Medical Journal, Eija Kalso, 01.01.2003  31.12.2011 
Acta Anaesthesiologica Scandinavica, Eija Kalso, 01.01.2004  31.01.2011 
Journal of Pain and Symptom Management, Eija Kalso, 01.01.2004  31.12.2011 
Anesthesia and Analgesia, Eija Kalso, 01.01.2005  31.12.2011, United States 
Anesthesiology, Eija Kalso, 01.01.2005  31.12.2011, United States 
Journal of Pain, Eija Kalso, 01.01.2008  31.12.2011 
Proceedings of the National Academy of Sciences, Eija Kalso, 01.01.2010  31.12.2010 
Jari Lilja 
British Journal of Clinical Pharmacology (1-3 articles annually), Jari Lilja, 01.01.2005  … 
Clinical pharmacology and therapeutics (1-3 articles annually), Jari Lilja, 01.01.2005  … 
Journal of pharmacy and pharmacology (1-3 articles annually), Jari Lilja, 01.01.2005  … 
Pertti Neuvonen ,  
Clinical Pharmacokinetics, reviewer, Pertti Neuvonen, 1980  2010 
European Journal of Clinical Pharmacology, reviewer, Pertti Neuvonen, 1980  2010 
Suomen Lääkärilehti, Pertti Neuvonen, 1990  2010, Finland 
Basic and Clinical Pharmacology and Toxicology, reviewer, Pertti Neuvonen, 2000  2010 
International Journal of Clinical Pharmacology and Therapeutics, reviewer, Pertti Neuvonen, 2000  2010 
Human and Experimental Toxicology, Pertti Neuvonen, 2004  2005, United Kingdom 
British Journal of Clinical Pharmacology, reviewer, Pertti Neuvonen, 2005  2010 
Clinical Pharmacology &amp; Therapeutics, reviewer, Pertti Neuvonen, 2005  2010 
Drugs, reviewer, Pertti Neuvonen, 2005  2010 
Annals of Medicine, reviewer, Pertti Neuvonen, 2010  2011 
Chemical Research and Toxicology, reviewer, Pertti Neuvonen, 2010  … 
Expert Opinion on Drug Metabolism and Toxicology, reviewer, Pertti Neuvonen, 2010  … 
Xenobiotica, reviewer, Pertti Neuvonen, 2010  … 
Mikko Niemi ,  
British Journal of Clinical Pharmacology, Mikko Niemi, 2005  … 
Current pharmacogenomics, Mikko Niemi, 2005  … 
Drug Safety, Mikko Niemi, 2005  … 
Journal of Clinical Pharmacology, Mikko Niemi, 2005  … 
Naunyn-Schmiedeberg's Archives of Pharmacology, Mikko Niemi, 2005  … 
Pharmacogenetics &amp; Genomics, Mikko Niemi, 2005  … 
Pharmacological research, Mikko Niemi, 2005  … 
Clinica Chimica Acta, Mikko Niemi, 01.01.2006  … 
Clinical Pharmacokinetics, Mikko Niemi, 2006  … 
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Clinical Pharmacology &amp; Therapeutics, Mikko Niemi, 2006  … 
European Journal of Clinical Pharmacology, Mikko Niemi, 2006  … 
Arteriosclerosis, Thrombosis, and Vascular Biology, Mikko Niemi, 2008  … 
British Journal of Pharmacology, Mikko Niemi, 2008  … 
Pharmacogenomics, Mikko Niemi, 2008  … 
The Journal of Clinical Investigation, Mikko Niemi, 2009  … 
The Pharmacogenomics Journal, Mikko Niemi, 2009  … 
Drug Metabolism &amp; Disposition, Mikko Niemi, 2010  … 
Editor of special theme number 
Eija Kalso ,  
Drug Discovery Today: Disease Mechanisms, Eija Kalso, 01.01.2005  31.01.2005, Netherlands 
Mikko Niemi ,  
British Journal of Pharmacology, Mikko Niemi, 2008 
Duodecim, Mikko Niemi, 11.2008, Finland 
Assessment of candidates for academic posts 
Janne Backman ,  
Reviewer for Docentship, Tapio Kuitunen, Janne Backman, 11.2008  04.2009, Finland 
Kaarlo Hoppu ,  
Assessment of candidates for associate professorship, Kaarlo Hoppu, 2008, Australia 
Pertti Neuvonen ,  
Evaluation of candidate for the Professorship in Pharmacology, University of Helsinki, Pertti Neuvonen, 2007 
Revierwer for Docentship, Esko Kankuri, Pertti Neuvonen, 15.09.2009  15.11.2009 
Reviewer for Professorship (fixed term)., Pertti Neuvonen, 01.10.2009  25.11.2009 
Evaluation of candidate for the Professorship in Pharmacology, University of Turku, Pertti Neuvonen, 10.03.2010  24.04.2010 
Membership or other role in research network 
Janne Backman ,  
Pharmacokinetic variability research network, member, Janne Backman, 2005  … 
Kaarlo Hoppu ,  
Global Research in Paediatrics (GRIP), Kaarlo Hoppu, 2009  … 
Heli Malm ,  
European Network of Teratology Information Services (ENTIS), Heli Malm, 1997  … 
Organization of Teratology Information Specialists in North America (OTIS), Heli Malm, 1997  … 
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), Heli Malm, 2006  … 
Serotonergic Modulation of Brain Development : Genetic and Pharmacologic Influences on structure, function and behavior, Heli Malm, 
2010  … 
Pertti Neuvonen ,  
Member of Drug Interaction Research Group, Pertti Neuvonen, 1990  2011 
Professor of Clinical Pharmacology, University of Helsinki, Pertti Neuvonen, 1992  2011 
Board Member of the Clinical Drug Research Graduate School, Pertti Neuvonen, 1995  2011 
Founder and Leader of the Clinical Drug Research Graduate School, Pertti Neuvonen, 01.01.1995  2011, Finland 
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Mikko Niemi ,  
European Research Network on Pharmacogenetics/genomics, Mikko Niemi, 2007  … 
International Transporter Consortium, Mikko Niemi, 2008  … 
Membership or other role in national/international committee, council, board 
Janne Backman ,  
Ethics Committee for Studies in Healthy Subjects and Primary Care, member and secretary, Janne Backman, 12.1999  04.2005 
Clinical Drug Research Graduate School, Board member, Janne Backman, 01.2005  … 
Coordinating Ethics Committee, Member, Janne Backman, 04.2005  30.09.2010 
Finnish Society for Clinical Pharmacology and Therapeutics, Board Memeber, Janne Backman, 15.03.2007  …, Finland 
EACPT, Delegate to the Council, Janne Backman, 2009  … 
Finnish Society for Clinical Pharmacology and Therapeutics, Chairman, Janne Backman, 19.03.2010  …, Finland 
National Committee on Medical Research Ethics, Member, Janne Backman, 01.10.2010  … 
Kaarlo Hoppu ,  
IUPHAR, Sub-Committee for Paediatric Clinical Pharmacology, Board, Chairman 2004-2010., Kaarlo Hoppu, 2004  2010 
EMEA/CHMP, Paediatric Working Party (PEG), Vice Chairperson, Kaarlo Hoppu, 2005  2007 
FINPEDMED - Finnish Investigators Network for Pediatric Medicines, leader 2007-2010, Kaarlo Hoppu, 2007  2010 
European Society for Developmental Pharmacology (ESDP), Board member; 2008, Kaarlo Hoppu, 2008 
European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), Scientific Committee, Member 2010-, Kaarlo Hoppu, 
2010  … 
IUPHAR, Section of Pediatric Clinical Pharmacology, Chairman 2010-, Kaarlo Hoppu, 2010  … 
Annikka Kalliokoski ,  
Lääkäripäivät 2009 ja 2010 "Lääkehoidon ajankohtaisia kysymyksiä", Annikka Kalliokoski, 01.05.2008  … 
Kelan sosiaalilääketieteellinen neuvottelukunta ja sen lääkejaosto, Annikka Kalliokoski, 01.03.2010  … 
Lääkepolitiikka 2020-valmisteluryhmät, Annikka Kalliokoski, 03.05.2010  31.12.2010 
Eija Kalso ,  
Suomen Kivuntutkimusyhdistys, tutkimustoimikunnan pj, Eija Kalso, 01.01.2001  31.12.2011, Finland 
Scandinavian Society for Anaesthesiology and Intensive Care Medicine, Postgraduate Course in Pain Management, board member, 
Eija Kalso, 01.01.2002  31.12.2010 
International Association for the Study of Pain, councillor, Eija Kalso, 01.01.2003  31.12.2008, United States 
International Association for the Study of Pain, president, Eija Kalso, 01.01.2009  31.12.2014, United States 
Heli Malm ,  
European Network of teratology Information Services (ENTIS), Heli Malm, 2009  … 
Pertti Neuvonen ,  
Board Member, Finnish Society of Clinical Pharmacology, Pertti Neuvonen, 1994  2009 
Chairman, Coordinating Ethics Committee of the HUS Hospital District, Pertti Neuvonen, 2000  2005 
Director of the Diagnostic-Therapeutic Department, Intitute of Clinical Medicine, Faculty of Medicine, Pertti Neuvonen, 2002  2011 
Member of Steering Committee - MD PhD Program of the Faculty of Medicine, University of Helsinki, Pertti Neuvonen, 2007  2011 
Member of Scientific Board, Helsinki University Pharmacy Grant Committee, Pertti Neuvonen, 01.01.2010  31.12.2010 
Mikko Niemi ,  
Coordinating Ethics Committee, Member, Mikko Niemi, 2009  … 
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Finnish Society of Clinical Pharmacology, Secretary, Mikko Niemi, 2010  …, Finland 
Pharmaceutical Policy 2020 Working Group, Mikko Niemi, 2010, Finland 
Membership or other role in public Finnish or international organization 
Janne Backman ,  
Expert Group on Therapeutic Drug Monitoring, HUSLAB, Member, Janne Backman, 2004  … 
Finnish Medicines Agency, Expert reviewer, Janne Backman, 01.01.2005  31.12.2007, Finland 
Expert group on cardiovascular medicines, diuretics and cholesterol-lowering agents, Member, Janne Backman, 01.2009  12.2009, 
Finland 
Expert group on Therapeutic Drug Monitoring, HUSLAB, Chairman, Janne Backman, 03.2010  … 
Parlamentary Committee for Social Affairs and Helath, Expert, Janne Backman, 02.03.2010 
Samuel Israel Fanta ,  
Finnish Medicines Agency, expert reviewer, Samuel Israel Fanta, 2010, Finland 
Tarja Heiskanen ,  
HYKS-alueen Saattohoitotyöryhmä, jäsen, Tarja Heiskanen, 2010  …, Finland 
Kaarlo Hoppu ,  
WHO Geneve, Sveitsi, Expert Advisory Panel on Drug Evaluation, Member 2007-, Kaarlo Hoppu, 2007  … 
Tiina Annikki Jaakkola ,  
Terveiden koehenkilöiden ja perusterveydenhuollon eettinen toimikunta, HUS, Tiina Annikki Jaakkola, 01.05.2005  04.05.2005, 
Finland 
Annikka Kalliokoski ,  
Lääkelaitos, Annikka Kalliokoski, 01.01.2006  31.12.2006 
Lääkelaitos, Annikka Kalliokoski, 01.01.2007  … 
Eija Kalso ,  
Lääkelaitos/FIMEA, Eija Kalso, 01.01.2004  2011, Finland 
Terveydenhuollon oikeusturvakeskus, Eija Kalso, 01.01.2004  30.11.2008 
Potilasvahinkolautakunta, Eija Kalso, 01.01.2005  31.12.2011, Finland 
University of Rochester: Neuropathic pain treatment guidelines, Eija Kalso, 03.04.2005  04.04.2005, United States 
Yliopiston Apteekin hallituksen jäsen, Eija Kalso, 12.2006  12.2009, Finland 
HUSLabin hallituksen jäsen, Eija Kalso, 2007  2012, Finland 
University of Rochester, Eija Kalso, 31.05.2007  02.06.2007, United States 
Sosiaali- ja terveysalan lupa- ja valvontavirasto VALVIRA, Eija Kalso, 01.12.2008  30.11.2012, Finland 
Jari Lilja 
Lääkelaitos, Jari Lilja, 01.01.2005  31.12.2005, Finland 
Pertti Neuvonen ,  
Person in charge for specialist training in Clinical Pharmacology and Drug Therapy, Faculty of Medicine, University of Helsinki, Pertti 
Neuvonen, 1992  2011 
Member of the Helsinki and Uusimaa hospital district drug formulary committee, Pertti Neuvonen, 1993  2011 
Member of Advisory Board of Social Insurance Institution (KELA:n Sos. lääket. neuvottelukunnan jäsen), Pertti Neuvonen, 1996  2009 
Member of Drug Committee of Social Insurance Institution (KELA:n Sos.lääket. neuvottelukunnan Lääkejaoston jäsen), Pertti 
Neuvonen, 1996  2010 
Chairman of the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, Pertti Neuvonen, 2000  2005, Finland 
Member of the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, Pertti Neuvonen, 2000  2005, Finland 
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Board Member, Institute of Clinical Medicine, University of Helsinki, Pertti Neuvonen, 2003  2011 
STM:n lääke-, logistiikka- ja mater. jaosto, Pertti Neuvonen, 2003  2006, Finland 
ROHTO neuvottelukunta, Pertti Neuvonen, 2004  2009, Finland 
Secretary of the Medicine Section, Finnish Academy of Science and Letters, Pertti Neuvonen, 2005  2009 
Suomen kulttuurirahasto, Pertti Neuvonen, 01.01.2006  31.12.2006, Finland 
Vice Director, Institute of Clinical Medicine, University of Helsinki, Pertti Neuvonen, 2006  2011 
Board Member of the Helsinki and Uusimaa Hospital District Pharmacy, Pertti Neuvonen, 2009  2011 
Board Member of the HYKS-hospital district, Pertti Neuvonen, 2010  2011 
Membership or other role of body in private company/organisation 
Eija Kalso ,  
International Association for the Study of Pain, Eija Kalso, 22.08.2002  31.12.2011, United States 
European Opioid Conference, Eija Kalso, 14.02.2005  31.12.2011, United Kingdom 
Marja Pasanen ,  
Lääketieteen kandidaattiseura, Marja Pasanen, 01.01.2005  31.12.2005, Finland 
Participation in interview for written media 
Janne Backman ,  
Aesculapius -journal, Interview, Janne Backman, 2009, Finland 
Sanomalehti Kaleva, Interview, Janne Backman, 31.07.2009, Finland 
Sanomalehti Karjalainen, Interview, Janne Backman, 12.07.2009, Finland 
Suomen Lääkärilehti (Finnish Medical Journal), Interview, Janne Backman, 2009, Finland 
Apteekkari -journal, Interview, Janne Backman, 2010, Finland 
Reseptori -journal, Interview, Janne Backman, 2010, Finland 
Terveydeksi! -journal, Interview, Janne Backman, 2010, Finland 
Samuel Israel Fanta ,  
Iltalehti, Samuel Israel Fanta, 05.07.2007, Finland 
Kaarlo Hoppu ,  
Helsingin Sanomat, Kaarlo Hoppu, 18.02.2006, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 10.01.2007, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 01.02.2008, Finland 
Keskisuomalainen, Kaarlo Hoppu, 25.02.2008, Finland 
Kainuun Sanomat, Kaarlo Hoppu, 01.09.2009, Finland 
Uusi Suomi, Kaarlo Hoppu, 08.04.2009, Finland 
Eija Kalso ,  
Studia Medicina, Eija Kalso, 19.04.2006, Finland 
Heli Malm ,  
KELA- lehdistötiedotus, Heli Malm, 13.06.2003  …, Finland 
YLEn uutiset, Heli Malm, 13.06.2003  …, Finland 
Pertti Neuvonen ,  
Interview (by Juha Merimaa) about Highly Cited Scientists in University of Helsinki, Pertti Neuvonen, 2010, Finland 
Interview (by Marita Kokko) about Top Science regarding Drug Interactions for the periodical "Apteekin Hyllyltä", Pertti Neuvonen, 
09.2010  10.2010, Finland 
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Mikko Niemi ,  
Viikon kollega, Mikko Niemi, 11.2008, Finland 
Dinosaurusten aika on ohi, Mikko Niemi, 08.2010, Finland 
Geenitestaus mullistaa lääkehoidon, Mikko Niemi, 01.2010, Finland 
Lääkkeet geenien mukaan, Mikko Niemi, 10.2010, Finland 
Nopea testi löytää geenivirheen, Mikko Niemi, 04.2010, Finland 
Perintötekijät vaikuttavat lääkkeiden tehoon ja turvallisuuteen, Mikko Niemi, 06.2010, Finland 
Marja Pasanen ,  
Duodecim, Marja Pasanen, 2007, Finland 
Helsingin Sanomat, Marja Pasanen, 18.12.2008, Finland 
Suomen Lääkärilehti, Marja Pasanen, 2009, Finland 
Suomen Lääkärilehti, Marja Pasanen, 2010, Finland 
Yliopistolehti, Marja Pasanen, 2010, Finland 
Participation in radio programme 
Eija Kalso ,  
Yleisradion haastattelu, Eija Kalso, 07.10.2005  31.12.2011, United States 
YLE Radio Peili, Eija Kalso, 02.06.2006  31.12.2011, Finland 
Pertti Neuvonen ,  
Interview (by Katariina Lahtonen) about "Drug interactions" in Radio Suomi, Ajantasa and YLE Areena, Pertti Neuvonen, 15.12.2010, 
Finland 
Mikko Niemi ,  
Reseptori, Mikko Niemi, 07.2010, Finland 
Participation in TV programme 
Janne Backman ,  
"Akuutti"-TV-program, Interview, Janne Backman, 02.06.2006, Finland 
Kaarlo Hoppu ,  
Yle; Sienikoulu, Kaarlo Hoppu, 2007, Finland 
Heli Malm ,  
Yle aamu-tv, Heli Malm, 23.11.2010, Finland 
Pertti Neuvonen ,  
Interview by TV (Nelosen Uutiset) about toxicity of hand desinfectans in children, Pertti Neuvonen, 22.09.2009, Finland 
Participation in interview for web based media 
Janne Backman ,  
Iltalehti -journal, Interview, Janne Backman, 22.07.2009, Finland 
Samuel Israel Fanta ,  
Helsingin Sanomat, Samuel Israel Fanta, 05.01.2007, Finland 
Kaleva, Samuel Israel Fanta, 04.07.2007, Finland 
Helsingin Sanomat, Samuel Israel Fanta, 03.08.2008, Finland 
Ilkka, Samuel Israel Fanta, 08.04.2009, Finland 
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Kaarlo Hoppu ,  
Helsingin Sanomat, Kaarlo Hoppu, 14.04.2006, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 09.10.2007, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 09.10.2007, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 25.05.2007, Finland 
Helsingn Sanomat, Kaarlo Hoppu, 09.10.2007, Finland 
Suomen Lääkärilehti, Kaarlo Hoppu, 23.08.2007, Finland 
mtv3.fi/uutiset, Kaarlo Hoppu, 02.10.2007, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 02.09.2009, Finland 
Helsingin Sanomat, Kaarlo Hoppu, 02.09.2009, Finland 
Yle, Kaarlo Hoppu, 26.08.2009, Finland 
Suomen Lääkärilehti, Kaarlo Hoppu, 21.01.2010, Finland 
mtv3.fi/uutiset, Kaarlo Hoppu, 16.06.2010, Finland 
Heli Malm ,  
Yle Terveys, Heli Malm, 14.12.2005, Finland 
Helsingn sanomat, Heli Malm, 16.11.2010, Finland 
Uusi Suomi, Heli Malm, 23.11.2010, Finland 
mtv3.fi/uutiset, Heli Malm, 08.11.2010, Finland 
Mikko Niemi ,  
Tieteen näkökulma, Mikko Niemi, 01.2010, Finland 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Backman J 
Basic statistics 
Number of publications (P) 184 
Number of citations (TCS) 2,327 
Number of citations per publication (MCS)  13.02 
Percentage of uncited publications 11% 
Field-normalized number of citations per publication (MNCS)   2.38 
Field-normalized average journal impact (MNJS)   1.58 
Field-normalized proportion highly cited publications (top 10%)   2.70 
Internal coverage    .91 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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